Podcasts about MDS

Scrubs and Subpoenas: Nursing Scope of Practice - A $150 Million Mistake Part 1 SUMMARY: Scrubs and Subpoenas: Nursing Scope of Practice is a podcast series that explores the critical role of nursing scope of practice in ensuring patient safety and reducing malpractice claims. Through real-life malpractice cases, this series provides insights into the boundaries of nursing responsibilities, the consequences of exceeding or neglecting these boundaries, and actionable strategies to align practice with legal and ethical standards. Each episode serves as a cautionary tale and a guide to fostering accountability, transparency, and excellence in nursing care.        In this episode, we dive into the largest malpractice case ever filed against a nurse practitioner. This story begins with a young family NP working alone in a rural, four bed emergency room, caring for a patient rushed in after a syncopal event and a subsequent head injury sustained in the ER. Lack of resources and ineffective protocol blocked proper care for this patient, leading to a catastrophic pulmonary embolism. We dive into the incongruence of court protections for NPs vs. MDs, and the detrimental implications of restrictive practice scopes. Explore the connections between healthcare deserts and poor patient outcomes, and where NPs fit into this complex puzzle.  ---Nurses may be able to complete an accredited CE activity featuring content from this podcast and earn CE hours provided from Elite Learning by Colibri Healthcare. For more information, click hereAlready an Elite Member? Login hereLearn more about CE Podcasts from Elite Learning by Colibri HealthcareView this podcast course on Elite LearningSeries: Scrubs and Subpoenas: Nursing Scope of Practice

Scrubs and Subpoenas: Nursing Scope of Practice - A $150 Million Mistake Part 2  SUMMARY: Scrubs and Subpoenas: Nursing Scope of Practice is a podcast series that explores the critical role of nursing scope of practice in ensuring patient safety and reducing malpractice claims. Through real-life malpractice cases, this series provides insights into the boundaries of nursing responsibilities, the consequences of exceeding or neglecting these boundaries, and actionable strategies to align practice with legal and ethical standards. Each episode serves as a cautionary tale and a guide to fostering accountability, transparency, and excellence in nursing care.        In this episode, we dive into the largest malpractice case ever filed against a nurse practitioner. This story begins with a young family NP working alone in a rural, four bed emergency room, caring for a patient rushed in after a syncopal event and a subsequent head injury sustained in the ER. Lack of resources and ineffective protocol blocked proper care for this patient, leading to a catastrophic pulmonary embolism. We dive into the incongruence of court protections for NPs vs. MDs, and the detrimental implications of restrictive practice scopes. Explore the connections between healthcare deserts and poor patient outcomes, and where NPs fit into this complex puzzle. ---Nurses may be able to complete an accredited CE activity featuring content from this podcast and earn CE hours provided from Elite Learning by Colibri Healthcare. For more information, click hereAlready an Elite Member? Login hereLearn more about CE Podcasts from Elite Learning by Colibri HealthcareView this podcast course on Elite LearningSeries: Scrubs and Subpoenas: Nursing Scope of Practice

Ladies and gentlemen, welcome to another episode of the Cha Cha Album Review Series on the Cha Cha Music Review Podcast, my name is Hafeestonova, Your Musical plug, the Creator of the Energy Force and the African Music Amplifier.In today's episode I will talking about Burna Boy's album titled No Sign of WeaknessPress the Play Button to listen Artist: Burna BoyAlbum: No Sign of WeaknessFeatured Artist: Travis Scott, Mick Jagger, Stromae, ShaboozeyProducers: P2J, OTIS, Telz, Dre SkullMajor Seven, Niph Keys, Mds, Stromae, Jay SynthsYear: 10th of July, 2025Tracks: 16 tracksAlbum Link: https://open.spotify.com/album/2fXaK76zsSLaAMwCyCqKQL?si=21c32888aa114d90

As more states transition to PDPM for Medicaid, therapy is no longer the primary driver of case mix index (CMI). So where do providers turn next?In this episode, Melissa Brown, COO of Gravity Healthcare Consulting, sits down with Dr. Rehan Shah, nephrologist and co-founder of CardioRenal Vision (CRV), to explore how cardiology, nephrology, and pulmonology services can transform PDPM Medicaid outcomes.Together, they discuss:Why therapy-driven CMIs are declining under PDPM MedicaidHow specialty physician programs improve documentation, acuity capture, and reimbursement accuracyThe power of on-site care models—from dialysis to respiratory therapy—to reduce hospitalizations and boost CMIPractical steps for aligning physicians, MDS coordinators, and facility leadershipIf your organization is preparing for PDPM Medicaid—or already navigating the transition—this episode offers actionable insights to help you strengthen performance, accuracy, and margins under the new model.

In this week's episode, hosts Ryan Baxter and Mark Ambrogio interview Meghan Voll, a PhD candidate in Media Studies here at Western University. GradCast listeners will recognize Meghan's voice, as Meghan served as a long-time host and Social Media Manager for this show.  This is Meghan's second time with us as a guest, as she approaches the conclusion of her doctorate, for those interested, Meghan's first episode, as a guest, can be heard here. Meghan studies the interaction between economic value and values on mobile dating platforms such as Tinder, Hinge, and Coffee Meets Bagel, drawing from the political economy of communication, mobile dating studies (MDS) and critical data studies (CDS). Ryan and Mark engage with Meghan on these ideas, asking about the intersection between so-called "soft values" (such as honesty and loyalty) and economic value ($). They also ask Meghan about her field research, interviewing human subjects, and the steps involved in obtaining ethics approval. Recorded on Tuesday, November 5, 2025 Produced by Mark Ambrogio and Kelly Wang Theme song provided by FreeBeats.io (Produced by WhiteHot)

In this episoe we're talking about how to feel like a priority in your relationship... without slipping into overthinking, over‑analyzing every text, or feeling like you're “asking for too much.” This episode is for you if: • You know they care about you… but you can't always feel it • You find yourself checking for proof or reassurance • You are tired of being the one initiating, planning, or emotionally leading • Your brain does wind sprints when there's space or distance in the relationship • You're successful in every other area of life, but your nervous system goes ✨ feral✨ in love   Trust me, I've lived this. I went from anxiously attached (and chronically exhausted from managing the relationship in my head) to actually feeling chosen, safe, and prioritized in a secure partnership. And we're unpacking exactly how that shift happens today.

Vous aimez notre peau de caste ? Soutenez-nous ! https://www.lenouvelespritpublic.fr/abonnementUne émission de Philippe Meyer, enregistrée en public à l'École alsacienne le 2 novembre 2025.Avec cette semaine :Akram Belkaïd, journaliste au Monde diplomatique.Jean-Louis Bourlanges, essayiste, ancien président de la Commission des Affaires étrangères de l'Assemblée nationale.Antoine Foucher, consultant, spécialiste des questions sociales, auteur de Sortir du travail qui ne paie plus.Lucile Schmid, présidente de La Fabrique écologique et membre du comité de rédaction de la revue Esprit.BILAN DE L'EXAMEN DU PLFLes députés ont commencé le 24 octobre l'examen de la partie recettes du projet de loi de finances (PLF), à l'Assemblée nationale.Après les trois premiers jours de débat à l'Assemblée nationale, les députés ont dégradé d'environ 4 Mds d'€ l'équilibre de la copie initiale. Lundi, la hausse de 2 Mds d'€ de la surtaxe sur les bénéfices des grandes entreprises a été votée à l'initiative du gouvernement, mais contre son camp. Les députés ont également adopté une mesure plus favorable aux entreprises, en votant l'article 11 du PLF, qui prévoit de reprendre l'an prochain la baisse de la cotisation sur la valeur ajoutée des entreprises, dont l'exécutif souhaite la suppression progressive pour « soutenir la dynamique de réindustrialisation ». Mercredi, les députés ont continué à détricoter la copie budgétaire du gouvernement avec l'adoption de deux amendements déposés par LFI : l'un pour élargir le champ d'application de l'impôt minimum de 15% sur les bénéfices des multinationales, l'autre pour instaurer une taxe exceptionnelle sur les superdividendes. De son côté, le RN a fait adopter grâce à l'abstention de la gauche une taxe de 33% sur les rachats d'actions qui, selon lui, rapporterait 8 Mds d'€. Face à ces revers pour le gouvernement, le bloc central a dénoncédepuis mardi une « surenchère fiscale ». Vendredi, l'article 3 du projet de loi sur le budget : la taxation des holdings a été adoptée par 224 députés, contre 10. La gauche s'est abstenue. La taxe Zucman sur les très hauts patrimoines a été largement rejetée, ainsi que sa version allégée, malgré la pression du PS. Vendredi soir, les députés ont lesté le budget Lecornu près de 45Mds€ de taxes supplémentaires (notamment la taxation proportionnelle des multinationales : 25Mds€, l'extension de la taxe sur les rachats d'actions : 8Mds€, la surtaxe de l'Impôt sur les Sociétés : 6Mds€, et dans la nuit un impôt sur la fortune improductive ...) Le Premier ministre a annoncé de nouvelles discussions avec les différents groupes parlementaires durant ce week-end. Les débats reprendront lundi.Les députés arrêteront leurs discussions sur le PLF lundi soir, avant de s'attaquer au projet de loi de financement de la Sécurité sociale à partir de mardi. Après son vote, prévu le 12 novembre, les débats pourront reprendre sur les recettes de l'État, pour enchaîner sur la deuxième partie du PLF, concernant les dépenses. Les projets de loi de finances et de financement de la sécurité sociale doivent être adoptés avant le 31 décembre. Les délais sont serrés, entre promesse de ne pas recourir au 49-3 et débats sur la réforme des retraites.Chaque semaine, Philippe Meyer anime une conversation d'analyse politique, argumentée et courtoise, sur des thèmes nationaux et internationaux liés à l'actualité. Pour en savoir plus : www.lenouvelespritpublic.frHébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

In this powerful Ask Dr. Tony episode, Dr. Tony Ebel addresses the recent wave of anti-chiropractic content flooding social media from conventional medical doctors. Rather than responding with anger, Dr. Tony offers a thoughtful, science-based perspective on why natural, neurologically-focused healthcare is exploding in popularity—and why some in the medical community feel threatened by it.Dr. Tony emphasizes that this isn't about "us versus them," but about giving families effective options. He shares his deep respect for emergency medicine (which saved his son Oliver's life) while making a compelling case for why drug-free, neurological approaches should be the first line of defense for chronic conditions. Throughout the episode, he dismantles common criticisms with updated neuroscience, real-world outcomes, and the principle that being effective matters more than being right.----Links & Resources:Listen to Oliver's Miracles Story Here.----Key Topics & Timestamps[00:01:00] - The Social Media Backlash: Dr. Tony addresses the recent flood of hateful, reactionary posts from MDs targeting chiropractors and natural health[00:03:00] - Straw Man Arguments Exposed: Breaking down how critics misrepresent what neurologically-focused chiropractors actually do [00:11:00] - Being Right vs. Being Effective: The real issue—are doctors focused on protecting their turf or serving families?[00:19:00] - Outcomes Over Opinions: Why we should compare real health results between conventionally-raised kids and those receiving neurological care[00:24:00] - Oliver's Story: Dr. Tony shares his personal gratitude for emergency medicine that saved his son's life[00:31:00] - The Nervous System Revolution: How modern neuroscience confirms what chiropractic has understood for 125+ years[00:38:00] - Medicine Saves Lives, Chiropractic Restores Lives: Defining the proper roles and sequencing of different healthcare approaches[00:42:00] - Understanding Before Criticizing: Why critics who never studied chiropractic can't accurately critique it[00:46:00] - Advice for Parents: How to handle the negativity and stay focused on what works for your family -- Follow us on Socials: Instagram: @pxdocs Facebook: Dr. Tony Ebel & The PX Docs Network Youtube: The PX Docs For more information, visit PXDocs.com to read informative articles about the power of Neurologically-Focused Chiropractic Care. Find a PX Doc Office near me: PX DOCS DirectoryTo watch Dr. Tony's 30 min Perfect Storm Webinar: Click HereSubscribe, share, and stay tuned for more incredible episodes unpacking the power of Nervous System focused care for children!

Dr. Alessandra Fanciulli discusses how the MDS criteria for the diagnosis of MSA has made an impact on the field, the status of biomarker research, and optimal targets for disease-modifying trials for MSA.

Prof. Susanne Schneider discusses all things dystonia. Listen as she reviews the revised MDS definition and classification system for dystonia, updates for neurodegeneration with brain iron accumulation, and the exciting future of genetic therapies.

In nearly every conversation I have about growing old, the same three concerns surface. No one wants to be really old and sick. No one wants to be really old and lonely. And no one wants to be really old and broke.Curtis Estes is a wealth management advisor who has been helping high-achievers design lives of purpose and longevity since 1991, when he began his career with Northwestern Mutual. Based in West Los Angeles with his wife and three children, Curtis brings over three decades of experience guiding clients through financial strategies that support vibrant, extended living. A journalism graduate from the University of Kansas, he's authored five books that reflect his passion for intentional living and legacy building. Curtis has also built a longevity community to give participants access to the latest insights from MDs, PhDs and longevity tech CEOs. Connect with Curtis: www.curtisestes.com.To View This Episode- https://youtu.be/d9g4VhXYbOk#philfriedrich #whoknewinthemoment #author #financialfreedom #longevity

In this Divorce Explored episode of We Chat Divorce, MDS co-founders Catherine Shanahan, CDFA®, and Karen Chellew, Legal Liaison, reveal how common financial shortcuts can cost divorcing couples thousands—sometimes hundreds of thousands—of dollars. From so-called “honesty policies” that skip verification, to misclassifying home-sale proceeds as income, to cashing out retirement accounts too soon, Catherine and Karen unpack the real impact of assumptions, missing documents, and misunderstood advice. They'll show you why verified data—not verbal promises—is the only way to protect your financial future. Whether you're preparing for mediation, negotiating a settlement, or already divorced, this episode will help you spot red flags before they turn into regret. You'll Learn How To: Identify the red flags that signal financial shortcuts in divorce Understand when assets ≠ income in support calculations Avoid costly mistakes when dividing or liquidating retirement accounts Confirm accurate valuation dates and tax implications Use the MDS Financial Portrait™ to model real cash flow before you sign Resources Mentioned Free MDS Financial Assessment – discover your starting point The Divorce Financial Portrait™ – verified data = financial clarity MDS Community – connect for support and education Listen & Subscribe - Follow We Chat Divorce on Spotify, Apple Podcasts, and YouTube for weekly financial divorce insights that turn fear into focus, focus into knowledge, and knowledge into power. Learn more about your ad choices. Visit megaphone.fm/adchoices

Faron Pharmaceuticals Limited (AIM:FARN) CEO Dr Juho Jalkanen talked with Proactive's Stephen Gunnion about the latest clinical data presented at the European Society for Medical Oncology (ESMO) Congress in Barcelona on its lead asset, bexmarilimab, in high-risk myelodysplastic syndromes (MDS). Jalkanen described the data as “truly game changing,” highlighting that combining bexmarilimab with hypomethylating agents (HMAs) yielded an 85% response rate—compared to 40% with standard of care alone. Importantly, the complete remission rate reached 45%, which he described as “one of the highest ever seen in this field.” The company has secured orphan drug designation and received clear FDA guidance supporting the possibility of accelerated approval based on response rate, particularly complete remission. Jalkanen emphasised the importance of normalising blood counts in this patient population, many of whom are severely anaemic and neutropenic. He also discussed new biomarker data showing strong Clever-1 engagement, especially in bone marrow—where disease often hides from traditional chemotherapy. Jalkanen said this highlights bexmarilimab as a “truly disease-modifying agent.” On funding, Jalkanen confirmed Faron is well capitalised into next year, with further financing under exploration to support the upcoming registration trial, including partnering and fundraising initiatives. For more interviews and updates, head over to Proactive's YouTube channel. Don't forget to like this video, subscribe to our channel, and turn on notifications so you never miss future content. #FaronPharmaceuticals #Bexmarilimab #MDS #BiotechNews #ClinicalTrials #FDAApproval #OrphanDrug #Immunotherapy #CancerResearch #ProactiveInvestors

Watch on YouTubeJoin us on The Worship Keys Podcast. A special guest, Marcus Perry! He shares his journey from piano beginnings to becoming Music Director at Mt. Zion Church, one of the largest congregations in the U.S. Marcus talks about leading with excellence and humility, building community through music, and keeping the choir alive in today's church culture.Hear behind-the-scenes stories from the Choir Room, lessons from playing behind Fred Hammond, and practical advice for worship keys players and aspiring MDs. Plus, Marcus gives a sneak peek at his upcoming projects and a full Logic Pro breakdown coming soon.marcusgperrySupport the showThanks for listening! Subscribe here to the podcast, as well as on YouTube and other social media platforms. If you have any questions or suggestions for who you want as a featured guest in the future or a topic you want to hear, email carson@theworshipkeys.com. New episodes release every Wednesday!

Did you know that premature ejaculation is the most common form of sexual dysfunction on the planet? In a similar vein, experts estimate that erectile dysfunction impacts a staggering 30-50 million men in the U.S. alone. And some studies suggest that 1 in 10 men experiences delayed ejaculation.The truth is, sexual dysfunction affects millions and millions of men, but the experience is often one of being alone. Helpless. Feeling stuck or out of control. Common thoughts:"Why can't I get hard when I want the sex? I feel like my body's betraying me.""I'm so frustrated about cumming so fast -- I want sex to last.""What's the point of even going on a date if I know it's eventually gonna end up in the bedroom?""I'm terrified that I won't satisfy her sexually, and then she'll either humiliate me, leave me, or both.""What's wrong with me?"---Here, Luke reveals the one primary and often overlooked yet vitally important commonality that exists between all sexual dysfunction. As he puts it, “Western medicine has reduced it to it being all about blood flow...” and it's about way more than that.As a doctor of Chinese medicine, Luke brings a unique and potent perspective on the topic. The plain truth is that overcoming sexual dysfunction like erectile dysfunction, premature ejaculation, and delayed ejaculation is simply not about what you think it's about.---Work with usReady to go deeper than the podcast and take action? Jason and I can help you break old patterns and transform your sex & love life for good. To see if you're a fit for our flagship program, Pillars of Presence, book a call here. Start anytime. (https://evolutionary.men/apply/)---Memorable quotes:“I have to whisper about it in doctor's offices.""Shoutout to the men for whom Viagra or Cialis just don't work."“Men are conditioned, programmed, indoctrinated into carrying their pain alone."“I went to naturopaths and MDs and nothing touched it.”“I get that you can run 100 miles. Let's talk about your relationships.”“I could not RECEIVE help … like it could not get into my body.”“Your cock is your compass.”“This isn't about sex; this is about power.”“It's literally a miracle.”---Mentioned on this episode:Luke Adler: https://lukeadlerhealing.com/To book a call with me to discuss Sexual Mastery, just email me at dearmenpodcast at gmail dot com

Like many Canadian small towns, Carberry, MB had become a healthcare desert. In 2023, the small ER closed and the last doctor left. Carberry embarked on the fight of its life to get healthcare back. Just days before the first of two new MDs starts work, Dr. Brian Goldman visits Carberry to learn about the Herculean efforts it takes for one town to reinstate healthcare, and make sure they don't lose it again.

A proporção de domicílios em insegurança alimentar grave caiu de 4,1% para 3,2% em apenas dois anos de governo Lula. Houve redução da fome nas áreas rurais e urbanas e em todas as regiões do país. Os dados foram divulgados nesta sexta-feira (10) pelo IBGE.Sonoras:

MDs have main character energy, but don't ignore Physician Assistants. We talk a lot about medical students on this podcast, but at Iowa we also have a physician assistant program, one that's very well regarded, nationally. So to kick off national PA Week, we've got a bunch of PA students to talk about their profession. PA2s Emily Mazzeo and Abby Crow, and PA1s David Walker Hofbauer and Jake Groh talk about what it's like to study alongside MD students (something unique to Iowa), how they view their place in healthcare, how they knew they wanted to be a PA, and where they see their profession heading in the next few years. Hint: their profession is the 10th fastest-growing career in the US, with an enviable work-life balance, more mobility than MDs, and similar opportunities to specialize or go into primary care. BTW, you can find out more about the PA career, as well as the MD and biomedical science PhD programs, at our virtual conference next week! Episode credits: Producer: Emily Mazzeo and Abby Crow Co-hosts: Emily Mazzeo, Abby Crow, David Walker Hofbauer, Jake Groh We Want to Hear From You: YOUR VOICE MATTERS! We welcome your feedback, listener questions, and shower thoughts. Do you agree or disagree with something we said today? Did you hear something really helpful? Can we answer a question for you? Are we delivering a podcast you want to keep listening to? Let us know at https://theshortcoat.com/tellus and we'll put your message in a future episode. Or email theshortcoats@gmail.com. We need to know more about you! https://surveys.blubrry.com/theshortcoat (email a screenshot of the confirmation screen to

Dr. Monty Pal and Dr. Matteo Lambertini discuss a compelling global study on the clinical behavior of breast cancer in young BRCA1 and BRCA2 carriers, the association of pre-diagnostic awareness of BRCA status with prognosis, and the importance of identifying healthy people who are at risk of carrying the BRCA1/2 pathogenic variants. TRANSCRIPT Dr. Monty Pal: Well, hello everyone, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist, professor, and vice chair of medical oncology at the City of Hope Comprehensive Cancer Center in Los Angeles. Now, when we think about genetic testing, whether for patients diagnosed with breast cancer or for other family members of them, it seems to be widely underutilized. Today, we're going to be discussing a recently published study in the Journal of Clinical Oncology that reported on the clinical behavior of breast cancer and specifically young BRCA1 and BRCA2 carriers, and the association of pre-diagnostic awareness of BRCA status with prognosis. I thought this was just a fascinating piece, and I honestly couldn't wait to have this conversation. It's a really compelling paper that highlights the importance of identifying healthy people who are at risk of carrying the BRCA1/2 pathogenic variants, and really the need for genetic counseling and testing to inform people about early detection that could lead to a better prognosis. I'm really delighted to welcome the study's lead author, Dr. Matteo Lambertini. He really needs no introduction. He's very well known in the breast cancer world for his amazing contributions to fertility in the context of breast cancer, to pregnancy in the context of breast cancer, and genetic testing. He's an associate professor at the University of Genova, and a breast cancer medical oncologist at the San Martino Polyclinic Hospital in Genova, Italy.  Dr. Lambertini, thank you so much for joining us today. Dr. Matteo Lambertini: Thank you very much, Dr. Pal. It's a great pleasure. Dr. Monty Pal: Oh, thanks. And just FYI, if you're listening in and you want to hear our disclosures, they're all listed at the transcript of this podcast.  So, I poured through this paper [Clinical Behavior of Breast Cancer in Young BRCA Carriers and Prediagnostic Awareness of Germline BRCA Status] yesterday, Dr. Lambertini, and first of all, congratulations on this study. This was a huge international multicenter effort, 4,752 patients. How did you pool all these patients with young breast cancer? Dr. Matteo Lambertini: Thanks a lot for the question. Yes, this was an effort made by several centers all over the world. The main idea behind the creation of this network that we have named as BRCA BCY Collaboration, was to get as many data as possible in a sort of niche patient population in the breast cancer field, meaning women diagnosed with breast cancer at the age of 40 years or younger, and all of them being BRCA carriers. We know that around, in the Western world, around 5% of breast cancer cases are being diagnosed under the age of 40 years, and among them around 10-15% are BRCA carriers. So, I would say it's a relatively rare patient population where we did not have a lot of evidence to support our choices in terms of counseling on treatment, prevention, and oncofertility as well. That was the idea behind the creation of this network that includes many centers. Dr. Monty Pal: Yeah. You know, what's so interesting about this is that you sort of draw this line between patients who have BRCA testing at the time of diagnosis and then BRCA testing earlier in their course and then leading to a diagnosis perhaps. And I think that's where really sort of the dichotomy in outcome sits. Can you maybe elaborate on this and tell us about timing of genetic testing in this study and what that meant ultimately in terms of prognosis? Dr. Matteo Lambertini: In this specific analysis from this large network, including almost 5,000 women with breast cancer diagnosed at the age of 40 years or younger and being a BRCA carrier, we looked specifically into the timing of genetic testing because this is a retrospective study and the criteria for inclusion are those that I have just mentioned, so diagnosis at a young age plus carrying germline BRCA pathogenic or likely pathogenic variant. In this analysis, we have looked into the time the patient has got the genetic testing and particular we focused on two populations: those that were diagnosed, knowing already to be a BRCA carrier, and those that got tested after being diagnosed with breast cancer. And the main findings from this analysis have been that knowing to be a BRCA carrier was associated with a lower stage at the time of diagnosis, meaning more T1 tumors, so a tumor less than 2 cm, more node-negative disease, and this translated into less aggressive treatment, so less often axillary dissection, less often use of chemotherapy and anthracycline-based chemotherapy. And even more importantly, we have seen a better overall survival for those patients that were diagnosed already knowing to be BRCA carriers as compared to those tested after breast cancer diagnosis. These results after adjusting for all the confounding, stage, treatment and so on, there was not significant anymore, meaning that it's not the timing of test per se that is probably leading to a better survival, but it is the fact that knowing to be a BRCA carrier would likely translate into having access to all the preventive measures that we have in this setting and this will translate into an overall survival benefit, so in terms of saving more lives in young BRCA carriers. Dr. Monty Pal: I think it's such an important point, and it's one that I think might sound implicit, right, but it needs to be proven, I think, through a study like this. You know, the fact that finding this early, identifying the mutation, doing enhanced screening, and so forth, is really going to lead to superior clinical outcomes. One of the things that I think many people puzzle over, including myself, is what to do? I personally occasionally will see BRCA altered patients in the context of prostate cancer. But that's a very different population of individuals, right? Typically older men. In young females with BRCA mutation, I guess there's a specific set of considerations around reproductive health. You'd already highlighted preventive strategies, but what sorts of things should we be talking about in the clinics once a patient's diagnosed and once perhaps their breast cancer diagnosis is established? Dr. Matteo Lambertini: Yes, exactly. Knowing to be a BRCA carrier has a lot of implications from prevention to treatment to survivorship issues including reproductive counseling. And this is important not only for the patient that has been diagnosed with breast cancer but also for all the family members that will get tested and maybe identify with this sort of genetic alteration before diagnosis of cancer. Why this is important is because we have access to very effective preventive measures, a few examples: MRI screening, which starts at a very young age and normally young women don't have an effective screening strategy outside the BRCA field. Also, primary preventive measures, for example, risk-reducing surgery. These women are known to have a high risk of breast cancer and high risk of ovarian cancer. So the guidelines are suggesting to undergo risk-reducing salpingo-oophorectomy at a young age, so 35 to 40 years in BRCA1 carrier, 40 to 45 years in BRCA2 carrier. And also risk-reducing mastectomy should be discussed because it is a very effective way to prevent the occurrence of breast cancer. And in some situations, including the setting that we are talking about, so young women with breast cancer, BRCA carrier, also risk-reducing mastectomy has shown to improve overall survival.  On the other side, once diagnosed with breast cancer, nowadays knowing to be or not a BRCA carrier can make a difference in terms of treatment. We have PARP inhibitors in the early setting, in the adjuvant setting as well as in the metastatic setting. And in terms of survivorship implication, one of the critical aspects for young women is the oncofertility care which is even more complicated when we talk about BRCA carriers that are women candidates for gynecological surgery at a very young age. So this sort of counseling is even more complicated. Dr. Monty Pal: One of the other things, and this is subtle in your paper and I hope you don't mind me bringing it up, is the difference between BRCA1 and BRCA2. It really got me thinking about that because there are differences in phenotype and manifestation. Do you mind just expanding on that a little bit for the audience because I think that's a really important reminder that you brought up in the discussion? Dr. Matteo Lambertini: The difference between BRCA1 and BRCA2 carriers has been known that there are different phenotypes of breast cancer that are more often diagnosed in these two different populations. Normally BRCA1 carriers have a higher likelihood to develop a triple negative breast cancer as compared to BRCA2 carriers, more likely to develop a hormone receptor-positive HER2-negative disease. In this study, again, a specific population of young women with breast cancer, we have seen the same findings, mostly triple negative disease in BRCA1 carrier, mostly luminal-like disease in BRCA2 carrier. But what's novel or interesting from this study is to look also at the age at the time of diagnosis of this disease. And particularly in BRCA1 carriers, we should be sort of more careful about diagnosis of breast cancer and also other primary tumors including ovarian cancer because the risk of developing these malignancies is higher even at a younger age as compared to BRCA2 carriers. And this has implications also in the primary and secondary prevention that we were talking about earlier. Dr. Monty Pal: Oh, interesting. I guess the fundamental question then from your paper becomes, how do we get at the right patients for screening for BRCA1 and BRCA2? And I realize our audience here is largely oncologists who are going to be listening to this podcast, oncology providers, MDs, nurses, etc. But maybe speak for a moment to the general practitioner. Are there things that, for instance, a general practitioner should be looking for to say, “Wait a minute, this patient's high risk, we should consider BRCA1, BRCA2 testing or germline screening”? Dr. Matteo Lambertini: Yes, it's a very important question for the breast cancer community. After the updated ASCO guideline, the counseling is way easier because right now the age cutoff goes up to 65 years, meaning that all the patients diagnosed with breast cancer below the age of 65 years should be tested these days. And then above the age of 65, there are different criteria like triple-negative disease or family history. From a general practitioner standpoint, it's of course a bit more difficult, but knowing particularly the family history of the person that they have in front will be crucial to know if there are cases of breast cancer diagnosed at a young age, maybe triple-negative cases, knowing cases of ovarian cancer in first-degree relatives or pancreatic cancer in first-degree relatives, and of course cases of prostate cancer as well. So, I would say probably mostly the family side will be important from a general practitioner perspective.  From an oncology one, the other point that I think is important to stress also based on the data that we have shown in this publication is that having a case of breast cancer known to carry a BRCA pathogenic or likely pathogenic variant. It means that all the people around this case should get tested and if found to be BRCA carrier and healthy carrier, these people should also undergo the primary and secondary prevention strategies because this is very critical also to improve their outcomes and try to avoid the developing of breast or ovarian cancer, but also in the case of diagnosis of this disease, a diagnosis at an earlier stage, as we have seen in this paper. Dr. Monty Pal: Brilliant. I'm going to diverge from our list of questions here and close by asking a question that I have at the top of my mind. You're very young. I know our podcast listeners can't see you, but you're very, very young. Dr. Matteo Lambertini: Thank you. Thank you for that. Not so young but yeah. Dr. Monty Pal: You have nearly 300 papers. Your H-index is 67. You've already made these seminal contributions, as I outlined it from the outset, regarding fertility, regarding use of GnRH analogs, regarding pregnancy and breast cancer. What are you studying now? What are you really excited about right now that you're doing that you think might potentially be practice changing? Give us a little teaser. Dr. Matteo Lambertini: Yeah. Thanks a lot, Dr. Pal. Receiving this compliment from you is fantastic. So, thanks a lot for that. From my side, in terms of my research, I've been interested in the field of breast cancer in young women since the start of my training. I've had very good mentors from Italy, from Europe, from the U.S. I'm still interested in this field, so I think we still have a lot to learn to try to improve the care of young women with breast cancer. For example, the oncofertility care, which is something I worked a lot over the past years. Now with all the new treatment options, there's a sort of new chapter of oncofertility counseling. So, what's the impact of immunotherapy? What's the impact of the new targeted agents?  More on the genetic aspects, now we know that there's not only BRCA1 or BRCA2. There are a lot of other different genes that may increase the risk of breast cancer and other malignancies. And also for these genes, we really don't have a lot of evidence to counsel women on prognosis, treatment, prevention strategy. So we need to learn way more for this special patient population that are quite rare, and so we really need a multicenter academic effort to try to give some evidence in this field. Dr. Monty Pal: Yeah. It's tough because these are rare circumstances, but, you know, I think that you've done really well to sort of define some collective experiences that I think really define therapy. I mean, I just remember when I was in training 25 years ago, just reading through textbooks where all the experience around breast cancer and pregnancy was really just very sort of anecdotal almost, you know? And so it's great to see that the state of the science has moved forward.  Well, gosh, I really enjoyed our conversation today. I think your study really reminds us how powerful genetic information is in terms of improving outcomes. And, you know, hopefully this will lead some individuals to perhaps test more broadly in appropriate settings. So, thank you so much, Matteo, for joining us today with your fantastic insights on the ASCO Daily News Podcast. Dr. Matteo Lambertini: Thank you very much, Dr. Pal. It's a real pleasure. Dr. Monty Pal: And thanks to our listeners too. You'll find a link to Dr. Lambertini's study in the transcript of this episode. Finally, if you value the insights that you heard today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Thanks a ton. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:    Dr. Sumanta (Monty) Pal  @montypal  Dr. Matteo Lambertini @matteolambe   Follow ASCO on social media:     @ASCO on Twitter    ASCO on Bluesky   ASCO on Facebook     ASCO on LinkedIn     Disclosures:    Dr. Monty Pal:   Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview  Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical  Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis  Dr. Matteo Lambertini: Consulting or Advisory Role: Roche, Novartis, Lilly, AstraZeneca, Pfizer, MSD, Exact Sciences, Gilead Sciences, Seagen, Menarini, Nordic Pharma Speakers' Bureau: Takeda, Roche, Lilly, Novartis, Pfizer, Sandoz, Ipsen, Knight Therapeutics, Libbs, Daiichi Sankyo, Gilead Sciences, AstraZeneca, Menarini, AstraZeneca, Menarini Research Funding (Inst.): Gilead Sciences Travel, Accommodations, Expenses: Gilead Sciences, Daiichi Sankyo Europe GmbH, Roche

According to research from Gartner, buyer uncertainty leads to a 30% reduction in a buyer's ability to make a purchase decision at all. So, how can you create a buying experience that builds confidence, drives engagement, and ultimately improves win rates? Riley Rogers: Hi, and welcome to the Win-Win podcast. I’m your host, Riley Rogers. Join us as we dive into changing trends in the workplace and how to navigate them successfully. Here to discuss this topic is Annabel Hosking, Global Sales Enablement Manager at LexiNexis Risk Solutions. Thank you so much for joining us, Annabel. Just to kick us off, I’d love if you could tell us a little bit about yourself, your background, and your role. Annabel Hosking: Hi everyone. I currently work as a global sales network manager at LexisNexis Risk Solutions within the data services brand, so I’m very fortunate to work across. Four different brands that will work within the data space. And within my role, I lead the sales enablement team. We’re a global team. We’re a small team, small but mighty, and we work across methodology enablement. So all about our sales methodology, how we go to market, how our customers. Experiences. And I also work across all of our onboarding as well as all of our tech stack as well. So my role is really varied. I’m very lucky I get to work with some really great people across the world. And yeah, it was never a dull moment, I’ll say. RR: Isn’t that always the case? Small scrappy teams. Wearing a lot of hats and it’s always exciting. We’re super excited to have you here because I know you have experience spanning a lot of core parts of enablement, so I think there’s a lot to dig into there. Could you walk us through, because I think everybody’s story is different, maybe your professional journey and then how that background led you to enablement, and then how it’s kind of shaped your approach to enablement today. AH: Absolutely. I have what I like to think of as, and it comes from a podcast I’ve been listening to recently, it’s called Squiggly Careers, and I feel like my career was like a very squiggly career of how I ended up in enablement, because I did not at school think, oh, I’m gonna become a. Sales enabler whatsoever. But my background is very much actually in content management and platform management and communication. And how I moved into enablement was I was actually hired in my current company and one of the brands, the beginning of the pandemic. To essentially deliver enablement content. So I worked on delivery of content, content management, delivery of our Highspot system as well. And that was how I started to move into the enablement realm. And I will say it was completely unknown to me originally. I. Wasn’t even clear that I was doing sales enablement per se, but at least a good 18 months in my role here. I thought I was just delivering content and it wasn’t until working with vendors like Highspot where. That term enablement started to come out and it started to change, I suppose, how I delivered my content and it’s really come into its own where now I’m very fortunate where I’m have on my team who does phenomenal content and through my experience. It’s really understanding who my audience is, understanding how they like to consume their enablement, but also how can we consistently stay, um, ahead of what the trends are and how people like to change, how they like to consume, what they’re seeing A meeting was held by our team on Monday with the client team for the Zephyr project to review the status of the forthcoming Q3 launch campaign. The campaign, originally built as a omnichannel activation across CTV, paid social and programmatic display, is now subject to substantial midstream revisions—following newly surfaced client directives. The feedback introduce a material shift in strategic framing under a compressed delivery window. There will be a pivot as Zephyr deprioritizing the performance-tracking narrative to favor of a broader “everyday wellness and inclusivity” story which will require an immidiate reframe of our messaging, architecture and associated visuals. To addressed the revised scope, I've assigned immediate follow-ups actions across the team. Visual art will lead conversations with post-production around stock content intergration. Ad sales will recalibrating the media plan in light of the repositioned messaging and will coordinate with DSPs to avoid penalties related on insertion order delays. Copy desk is to be tasked with stripping all unsubstantiated medical claims from copy, implementing the new CTA and managing a parallel review with legal. We conduct a daily internal stand-up each morning through end of week to identify blockers. The next client check-in is scheduled for July 3rd, where we preview asset revisions and confirm compliance milestones. Final go/no-go is slated for July 7th at 17:00 PDT. We are proceeding with all mitigations in parallel, and escalated any dependency delays as they surface. day to day, because that has vastly changed as well in the last six years. So. Thankfully my background and being adaptable, working globally, working with a lot of different people has really helped shape that. Because you know, I always say if there’s one thing, so my career of, you know, working in content management and working with platforms, working in technology. It has really shaped who I am today because it’s all really embedded in those user Jo Journeys user stories, and that translates into what I hope is a good enablement experience. RR: Well, amazing. I love the phrase squiggly career. I think I am certainly going to have to steal that one, and I think it’s such a good way to describe how so many folks end up at enablement. You start in one place and you bring all of that knowledge that you acquire in that early discipline. Into enablement programming that’s more effective for it. And thinking about, you know, your background in content management and creating content and all of that fun stuff, I’d be curious to know how they kind of come together. So you recently spoke at Spark EA and highlighted the importance of the buying experience, so. What are you seeing as some of those biggest challenges in engaging today’s buyers and how are you addressing them? Maybe through content, maybe through enablement? What does that look like to you? AH: I mean, I think the buying experience today in 2025 is unlike anything we have seen. Ever. It is a completely different world for both salespeople and for buyers as well. And what I’m seeing is, you know, buyers are not only overwhelmed with information, they’re also inundated with it. There is so much content out there for a buyer to consume and not just through their sales individual. This is content that they can easily go and either get themselves or with things like AI and Copilot, they can have. Harness and surface to them. So that makes the role of the seller that much harder because we don’t always know what the buyer is viewing and whether it’s of value to them, and that means that their time, the buyer’s time is so precious. We are seeing that, you know, buyers, and I mentioned this when I was at Spark, there are so many people now involved in the buying decision. We’ve moved, I think it was from about three people a few years ago. We’re now at. Six to 10 people. And if you think about it, those are all new personas that sellers have to understand, have to get to know, potentially map out, connect with. And what’s really unfortunate is we’re also seeing that for a lot of sellers, our buyers are actually taking. Long to make a decision that they kind of get to a point of no decision. We’re at this decision fatigue. We’re a information fatigue, we’re a decision fatigue. And I think on the whole, our buyers are they tired. And I can talk as a buyer, myself as a customer, it’s really exhausting. And so what we try to encourage where I am in data services is sales have to differentiate themselves. If you wanna get in front of buyers nowadays, you have to think what are you bringing to the table that’s different from them? That’s a unique experience, that’s an experience that makes ’em feel important, makes ’em feel, listened to, makes them feel like they really can understand why we are doing business together. And that starts in how we as enablement get that content to our salespeople. If we are not able to identify the value that we are bringing as brands into that conversation, it becomes really hard for sales to know how to articulate that to the buyers as well. And so. As enablement, we are that bridge between the, a lot of other functions and the sales teams and the commercial teams of making sure that value identification is really clear. So by the time it reaches the buyer, they absolutely know why they’re having that conversation. They absolutely know what the value of that conversation is going to be. And that really does start with how are you getting that information into the hands of your salespeople? How are you making that content? Really accessible, really palatable as well. I think traditional enablement, we defer to a lot of very wordy, very long documents, which from experience, no salesperson really wants to read or look at or go through. So just as we’re seeing the buyers experience evolve, the enablement experience has to evolve as well in order to stay ahead of that and to give them the best experience to our salespeople. RR: I think you’re absolutely right on all of that. It is only getting more difficult, and as things change externally, you need to adapt internally. And so kind of thinking about how you’re making that change, and to your point, how you’re distributing materials in a way that is usable and usable for a sales audience that maybe isn’t gonna read 10 pages of written content. What would you say then is kind of the unique value for an enablement platform when it comes to helping sellers? Create and deliver these impactful and differentiated buying experiences that you’re looking for? AH: Oh, huge value, absolutely huge value. The power of enablement comes in the ability to be able to streamline that messaging. But in order to do so, we do need a channel to do that, you know, and that can’t exist. In ad hoc documents that you just hold on someone’s computer. Our journey with Highspot started many, many years ago. I think it was about sort five or six years ago, very early days for Highspot even themselves. And we set out with a mission statement, which was that Highspot would be a single source of truth holding up UpToDate relevant sales content. And I am happy to say that five years later we still maintain that mission statement. The platform has got bigger. There’s more people, there’s more content, as I’m sure you can imagine, but we have stuck to our statement that it is a single source of truth. It is up to date, it is valid information that sales are getting, but that all comes from having a channel with a witch to push that through to the sales audience. It just makes your role as an enabler that much easier, you know, day to day. As you know, we spoke about at the top of the call is no one day looks the same for enablement. It will always be different. There’ll be different priorities. There’ll be different go to market, there’ll be different initiatives. But if you know that at least you have somewhere that you can reliably put information in front of sales and then see how it’s being used, how it’s being impacted, how the seller is using it, how the buyer’s consuming it. Your role as enablement starts to become just a little bit easier. And so I would say for anyone who’s within the enablement sphere and looking at their tech stack, having a solid CMS is really gonna be a, a strong cornerstone of that. RR: I love the perspective on an enablement platform as kind of a source of consistency. Almost everything is changing. Your day in enablement is different. Buyers are behaving differently. Reps need to do different things to engage ’em, but at least you have one place that is reliable. But I will say, I know that. Strong buying experiences aren’t necessarily contingent just on technology. They also require a lot of hard work internally. And as one of the things that you, I’ve seen you mention on LinkedIn is that a core foundation of LexisNexis Risk Solution Services is ensuring that customers really recognize the value that you provide. And that kind of starts internally. With sales and leadership alignment. So I’m curious, how are you aligning those internal stakeholders so that way your teams are set up for success when they’re shaping those buyer experiences externally AH: with immense difficulty, I’ll say, and I think any enabler that sits here and says that it’s an easy job is lying through their team. It is, I think, one of the hardest, the hardest roles. Of enablement is getting everybody aligned, getting everyone to agree, and especially I work, as I say, across a lot of businesses. You know, I have four MDs, I have four heads of sales, I have a lot of sales leadership and a lot of sellers, and I’m sure that’s the case for a lot of people working in large enterprise organizations, stakeholders. Can be difficult to align, especially when you have a lot of different priorities and a lot going on. But what I would say is, is really identify what is the core value that you as a company or you as a business, as a brand can all agree on. Our MD has this thing, he says that all of our kickoffs, which is, you know, value is not on the lips of the seller, but is in the eyes of the customer. And that mission statement as it were. Has sort of brought all the stakeholders together to agree that even if there’s misalignment or disagreement on how we do things, we can all agree that we want to give the best experience for our customer and the best value to our customer. And so for enablement, it’s then saying, okay, so we have this mission statement, we have this belief that we want to be customer centric. We want to be value focused. What does that actually mean? For each internal stakeholder, what’s important for them? What are the metrics that they’re looking at day to day, month to month, quarter to quarter, and how is what we are doing with an enablement? How is it actually starting to impact that? Where is their focus? What are they going after? And the only way you are really gonna get those answers is by talking to your stakeholders. If you’re an enablement and you’re not a people person, it’s probably gonna be quite a tough job because a lot of our job is just talking. It’s talking with people, talking, you know, at people, sometimes listening to people, taking in information. I would say spend time with your stakeholders. You are there to listen first and foremost. You can’t solve every single problem that they come up with, and you shouldn’t try to. But if you can really understand what their world looks like and what’s really important to them, and what are the behaviors, what are the metrics that are gonna move the dial for your stakeholders? You’ll eventually start to map out, which is what we did. But actually a lot of them start to align. And even though they might be saying different things, the reality is that for a lot of sales leadership, they want similar things. You know, they want to have better pipeline hygiene, they wanna have higher wind rate. They wanna see, you know, large opportunity amounts more in the qualifying, the identify stage, that early sales stages, they wanna increase, you know, the ramping of new starters. We start to get these similar uniform metrics and so then we as enablement can start to work that into our strategy. Although we as enablement can really start to build what we are working on to align with our internal stakeholders and start to deliver for them. RR: I really appreciate that you had some really tactical and helpful tips in there, but also that you led with, this is not easy. That’s the big part, is there’s so many kind of lofty initiatives that you are like, how do I even tackle this? And it sounds so overwhelming. So I appreciate the acknowledgement there. Kind of wanna shift gears a little bit maybe towards some of the capabilities that you’re using and finding some success with. So one of the things that we’ve heard is that digital rooms have been a lever for kind of creating those differentiated buying experiences. So what are some of your best practices for creating effective digital rooms and then maybe getting your teams to leverage them. AH: Mm, absolutely. We have a brand who is using digital rooms really fantastically, and they’re teaching our other brands how they’ve used them. So, you know, I, I wholeheartedly agree they can make such a difference in the buying experience and if you’re not using them, you should a hundred percent be looking into where you can use them. So I would say when you are looking to start with a digital room is really understand. Why are you doing this? Like what’s the purpose of actually taking the time and the effort to work probably with your product marketing team or with your marketing teams as a whole to put together something that looks really professional. Looks on brand, but is also really easy for sales to go in and start to customize. I would recommend not having sales do it fully themselves. They have very busy day jobs, and I think if you’re gonna say to any sales person, okay, over to you to go and create this, you might run. Some adoption issues, however, working, you know, this is where your cross-functional working really becomes essential, is working with the individuals who can make good content, who can deliver good, uh, visuals, good framework for the salespeople to literally just be able to, within their sales cycle, adopt this, lift it, and send it to the customer. Because then we start to see, okay, where are we actually starting seeing the customer impact? Has it changed how the customer engages with the content? Are they revisiting? And so what we’ve seen is we’re actually looking at, you know, we see a much higher engagement rate when we have the customers viewing content through a digital room as opposed to simply. Static content, and we can see that obviously with the Highspot metrics, which you know, are a real gold dust when it comes to that. We can also see that, you know, we have repeat visits, so something that we wanted to drive was customers coming back and revisiting the content rather than just clicking in, seeing it once and then never viewing it again, was actually having that revisit of them continually coming back to their individual microsite, if you will. You know, we spoken a lot about a differentiated. Differentiated buying experience. And that can be challenging for salespeople because unless you are fortunate enough to only have you know four or five accounts, the likelihood is your book of business is probably quite vast. And so the expectation that you are consistently offering a differentiated variance for every single customer is just not sustainable. And so using these digital rooms, you are able to. Have, you know, a differentiated experience that is scalable. That it makes a buyer feel like it’s a really individualized experience when the reality is for sales, it’s probably quite an easy thing for them to put together, but it does take some uplift front end with your other teams and your cross departmental functions. RR: Yeah. I wanna double click it as something you said there, which was, if you’re asking reps to build it themselves, you’re probably not gonna see much in the way of adoption. I, I kind of wanna. Speak about that idea of what you can do to drive adoption more broadly. Because looking at the data, you’ve achieved a really impressive 82% recurring usage rate in Highspot. So in addition to that kind of approach to digital rooms, how are you driving adoption more broadly across your revenue teams, whether that’s internal reps, partners, whomever, what are you thinking about that’s helping you? Get people in the platform and keep them there. AH: Yeah. That’s been, you know, a metric we’re very proud of. And it’s been something where, you know, going back to what I said earlier, which is Highspot was set out to be the single source of truth. As soon as we turned on Highspot, for lack of a better word, we pretty much turned off every single other site. So there was nowhere else. For sales to go to get this information apart from this one platform. And I’ve seen this done various ways. I’ve seen people where they have, you know, duplicates and, oh, we’re doing a slow migration. We’re gonna keep SharePoint for a while, and then we’ll have Highspot as well. And you know, there’s no right answer to this, but ultimately, if you are looking to put out a message that this is your single source of truth, this is where you need to go to speak to sales. Our adoption has come because we really drove that and we continue to drive that. If you want content in front of sales, if you want success stories in front of sales, whatever it might be, it has to live in Highspot because there just simply isn’t anywhere else to go. And this is for a couple of reasons. The main one being that, you know, the actual management of the content is far easier. And if you think about the trickle down effect, the user needs the best experience possible. And so if they have all of this disjointed experience of going to multiple places to find multiple pieces of content that look different, that sound different, they’re not getting the best experience and they’re probably not gonna come back to Highspot. So for us, it’s really making sure I’m maintaining. The consistency in the user experience, and that comes from feedback as well. So we will regularly have feedback forums with our salespeople, with our sales leadership, and we’re very open within our team to hearing, listen, this is actually getting quite complicated to navigate. I dunno how to find content. And so then we as a team, as an enablement team, go, okay, what do we need to do to make it easier? How do we start to surface more content directly in front of our users? Because if they’re not having a good experience, then we are not doing our role as enablement. And you know, you don’t have to, if you do have a large sales team, you don’t have to have that verbatim feedback. You can use things like the search reports in Highspot to see, you know, what are people searching, what are the terms they’re looking for and the pieces of content, how can you start to surface that in front of them in a much easier way? Putting it on the homepage, putting it into their specific areas, really thinking about how you. Manage, maintain and govern that content to give your users a really solid experience. And that’s what we’ve done and it’s reflected, as I say, in the adoption and in the revisit rates as well. RR: I really like that you called out that search results report because I think that’s such a great way to kind of get a pulse on your people without having to go dig around and have a bunch of conversations. So thinking in addition to that, how do you leverage data and insights in the platform to help you inform and improve the programs you’re leading? AH: Yeah, absolutely. I mean, I have actually had to learn to, I suppose, step away from data slightly. Um, so that’s been feedback I’ve had as I’ve moved more into a, I suppose a leadership role is actually the data can’t always tell the whole story, although my heart and enablement goes, yes, it can, it can. But yeah, the. The, the scorecards that we have in high spots. So really for us, you know, looking at things like that play scorecard, we deliver a lot of sales plays. They’re the best way to get our enablement in front of people. They’re enjoyed and they’re liked by sales. But I can see very clearly what is the percentage of my audience that is viewing this play? How long are they spending? You know, what are the outcomes of the, you know, the business impact? At what point in the sales cycle as well? If there’s external content in there, for example, the marketing collateral, are they deploying this collateral and is it actually having any impact on the customer? Those sorts of insights. You just do not get anywhere else within any other content platform that we have. And so when it’s come to say, onboarding our marketing team or our product team into contributing content, being able to give them this insight helps them understand that the work they’re doing on building the content, maintaining the content is actually worth something because we can directly see the correlation with business outcome, which has always been one of our biggest challenges. Beyond that, our company does a lot with actually pulling the data out of Highspot. So we make use of the Highspot data lake, and we’ve actually pulled that into our own BI platform where we’ve started to look at things around, you know, how many channels and how much activity per opportunity are we seeing within sales. Something at the moment that we’d really drive on. Going back to that differentiated experience for the buyer is looking at a multi-channel approach when it comes to how we prospect and how we outreach. And that really started from using information that came from Highspot, looking at information that comes from Salesforce and going, okay, how many channels do people currently use when they’re outreaching? We’re only maybe seeing a couple, you know, one or two channels. But we know in today’s buying world that it’s gonna take between six to eight. Channels to get through to a buyer and to actually have a meeting. So what can we do to start to move the dial and start to build our programs across driving that? And so that’s how we use data and enablement is actually saying, what are we seeing today? What are the outcomes we want to see in the next quarter? What do we need to do in order to get there? There’s always a lot of talk on LinkedIn. I always see it about, you know, you need to be data driven and enablement. If you’re not offering insight, if you’re not offering analytics, you’re not doing your job. And that can be kind of hard to hear when actually, I think there’s almost too much data sometimes, and it can be quite complicated to understand. And this is why I, I personally really like how it is viewed in Highspot because the scorecards make it very accessible, very easy to consume, but also it doesn’t matter whether you’re an enabler, a seller, or a senior leader, you can be presented a scorecard and you can very quickly see what you need to get out of that and what your conclusions you’re drawing from it. RR: Yeah, I think it’s that. The difficulty of democratizing data into meaningful, actionable insights is sometimes impossible. You have so much at your disposal, and so making it useful is sometimes a challenge, so I love hearing that. You’re finding a way to use it well and inform your programs well. So we’ve heard a little bit about engaging buyers driving adoption. Tracking your impact and seeing how it’s kind of helping you do the things that you need to. So just one last question for you to close this out. For other enablement leaders looking to improve the buyer experience in today’s very digital first world, what is the biggest advice you would give ’em? AH: Oh, that’s a great question. I would say if you are in a position where you’re fortunate enough to be the buyer, think about how you want to experience that life cycle. You know, as someone who is a buyer day to day, as well as an enabler. You know, I always ask myself through, when we do our methodology onboarding, I will go and speak to the sales people about actually what it’s like from a buyer’s experience today, and that really helps. Give them that insight into what is sometimes a little bit of an elusive world that we know the buyer’s world, the buyer’s experience. So I would say for other enablers is how do you like to speak to your vendors? How often you know, what makes them stand out? What makes them noisy in your inbox, you know? When do you get those emails or outreach that you think, wow, I really wanna continue a conversation with that person. What did that person do? How can you bring that into your go to market? How can you bring that into your sales team if you’re an enabler who is perhaps not in the buying cycle? I would say. Spend time with your salespeople, really understanding the customer experience, and there are many ways that we can do this. Nowadays with technology, obviously everybody’s got call recording software, so we have a lot of our sales calls recorded. If you as an enabler are not digging in and really understanding what’s happening in those customer conversations, it’s going to be harder for yourself to be able to really get into the world of salespeople. So I would say, you know, you really need to experience. What the customer is going through. And that can be simply by having a look at those calls. Where were they successful? Where was there a positive outcome? Where did the buyer enjoy it? But then also where did the buyer sometimes mention things that were pains to them or where they would like to see improvements? What were the questions? That is where we really need our enablers to be on the front foot of really digging into the customer experience and almost spend as much time as you know with your customers, as you do with your salespeople, to really get that insight. RR: I think that’s fantastic advice to close on, is to put yourself in the buyer’s shoes, understand what they’re going through, and know for yourself what good looks like to you and drive that in your own business. So thank you again, Anabel. This has been a wonderful conversation full of all sorts of good insights that I really can’t wait to share with our community. I appreciate you joining us so much. AH: Thank you so much. Thank you so much for having me as well. Fantastic questions. RR: Amazing. Well, to our listeners, thank you for listening to this episode of the Win-Win podcast. Be sure to tune in next time for more insights on how you can maximize enablement successful Highspot.

The Eyes Have It! When they say "the eyes are the windows of the soul," could it be possible that the eyes are really telling us so much more about what is going on in our bodies than we realize? Are there secrets that could help you revitalize your energy and your overall health? Learn about iridology, a study used by MDs in Russia and Europe to decode what the iris is telling you about your own health, and about sclerology, the study of the red lines in the whites of your eyes and what secrets could be revealed. Did you know that Howard Hughes had sclerology practiced on him in the 1950s and he predicted some day the eyes may be used as the Rx of the future?   This show was originally part of the Optimal Order Season and first aired on 5-4-21.   For more information or to reach out to us go to www.bettynorlin.com, or our website, www.behealthyinahurry.com, where all our episodes are stored. You can search for any topic or subject.   We thank you for your years and support and wrapping up our final show soon. We are excited to share this with you!  

Amy is a world-renowned author who in 2022 toed the line of the iconic Marathon des Sables. The race planted seeds for a story, one of ultra-running and mystery. In June 2025, 'RUNNER 13' was released. Amy joins the podcast to discuss the book and her MDS story.     Runner 13 is a thriller that drops readers straight into a deadly stage race across the Sahara, echoing the notorious Marathon des Sables in Morocco. McCulloch's own experience running that event shapes every detail - the brutal desert landscape, the psychological toll, and the obsession with endurance that defines the sport. The story follows Adrienne, a once-great ultrarunner forced back into competition, and Stella, daughter of the race's manipulative director, Boones. His events, modelled on real-world extreme events, they aren't designed to be won, but to break runners. Central to the mystery is Runner 13, a symbol of both glory and doom. Told in sharp, cliff-hanging chapters that jump between present and past, the novel feels like Agatha Christie transplanted to the Sahara: a brutal race where survival, not victory, is the prize, and where Morocco's desert becomes both the setting and the trap.

00:00:00 - Intro 00:00:53 - Stage 4 Colon Cancer 00:31:14 - Myelodysplastic syndrome (MDS) 00:39:48 - Eye Issues - Shingles (Herpes Zoster) - Macular Edema - ERM (Epiretinal Membrane) 00:49:59 - TMJ (Temporomandibular Joint) -  Skin Issue - Stye - Neuralgia 00:58:29 - Female Reproductive Tonic 01:03:56 - Chronic Fatigue - Brain Fog - Overwhelmed - Toenail Fungus - Athlete's Foot 00:00:53 - Stage 4 Colon Cancer About 18 months later, the cancer returned—this time involving her ovaries, uterus, liver and peritoneal cavity. 00:31:14 - Myelodysplastic syndrome (MDS) It is a type that could potentially develop into acute leukemia in the future. 00:39:48 - Eye Issues - Shingles (Herpes Zoster) - Macular Edema - ERM (Epiretinal Membrane) I refused the last injection because I feel there has to be an alternative to this. 00:49:59 - TMJ (Temporomandibular Joint) -  Skin Issue - Stye - Neuralgia I have near constant pain/irritation on left side of my scalp.  00:58:29 - Female Reproductive Tonic Is there an issue with a woman in menopause, age 70, taking the Female Reproductive Tonic? 01:03:56 - Chronic Fatigue - Brain Fog - Overwhelmed - Toenail Fungus - Athlete's Foot I have healed fibromyalgia, suicidal thoughts, depression and autistic tendencies.

This week, the party concludes their clash with the elusive Skibrellon. As they take a moment to recover and regroup, an unexpected lesson unfolds—revealing the very real difference between DMDs and MDs. Spoiler: only one of them is useful when you're bleeding out.

Broadcast icon and breast cancer survivor Robin Roberts joins Sarah for an intimate conversation about the strength it takes to show up — especially when the cameras are off. Robin reflects on her groundbreaking career in sports journalism and morning television, the decision to go public with her diagnoses, and how surviving cancer and MDS – Myelodysplastic Syndrome – reshaped her sense of purpose. Robin and Sarah explore what it means to lead with grace, advocate for others, and live a life of visibility both behind the news desk and far beyond it. Follow Robin on Instagram here Leave us a voicemail at 872-204-5070 or send us a note at goodgame@wondermedianetwork.com Follow Sarah on social! Bluesky: @sarahspain.com Instagram: @Spain2323 Follow producer Misha Jones! Bluesky: @mishthejrnalist.bsky.social Instagram: @mishthejrnalist Follow producer Alex Azzi! Bluesky: @byalexazzi.bsky.social See omnystudio.com/listener for privacy information.

In this eye-opening episode, I sit down with Arthur Menard de Calenge, the visionary CEO and Founder of HAVN to delve into a topic that's often overlooked but critically important: EMF exposure and its impact on our health. We explore how the invisible radiation emitted by everyday devices—like cell phones, laptops, and Wi-Fi routers—can affect our fertility, hormone balance, and overall well-being. Arthur shares insights from over 2,200 peer-reviewed studies linking EMF exposure to adverse health effects, including decreased sperm count and motility, DNA damage, and increased oxidative stress. But it's not all doom and gloom. Arthur also discusses practical steps we can take to mitigate these risks, such as maintaining distance from emitting devices, using EMF meters to measure exposure, and adopting protective measures like switching to wired headphones. He also introduces HAVN's innovative WaveStopper™ fabric, inspired by spacesuit technology, which blocks 99.7% of EMF radiation and is incorporated into everyday clothing items like hats, underwear, and laptop pads. This conversation is a must-listen for anyone interested in understanding the science behind EMF exposure and learning actionable strategies to protect themselves in our increasingly connected world. Key Takeaways: EMF Exposure and Health: EMF exposure can have significant adverse effects on human health, particularly male fertility, through mechanisms like increased reactive oxygen species. Protective Measures: Simple everyday adjustments, such as removing cell phones from pockets and turning off Wi-Fi routers during sleep, can significantly reduce EMF exposure. HAVN's Product Innovation: HAVN offers a range of clothing and accessories designed to block EMF radiation, utilizing technology inspired by space suits. Scientific Support and Awareness: Over 2,200 studies have linked EMF exposure to various health risks, emphasizing the need for greater public awareness and precaution. Practical Benefits for Athletes: Top athletes, including Rudy Gobert, use HAVN products to enhance recovery and performance by reducing EMF-induced stress and enhancing heart rate variability. More About Arthur Menard de Calenge: Arthur Menard is a Forbes 30 Under 30 entrepreneur, TEDx speaker, and the founder of HAVN (havnwear.com), the world's first EMF-blocking apparel designed for daily wear. Trusted by doctors, elite athletes, and the U.S. Air Force, HAVN's patented WaveStopperTM fabric blocks 99.7% of radiation from everyday tech, helping reduce risks tied to fertility, hormones, and cognitive health. Since launch, HAVN has sold over 250,000 products to more than 70,000 customers worldwide. Arthur holds an MS in Biology & Engineering from AgroParisTech and an MBA from HEC Paris. His mission is to help people live longer, feel better, and thrive in a connected world. Website Instagram LinkedIn Connect with me! Website Instagram Facebook YouTube This episode is sponsored by Professional Co-op®, where clinicians gain exceptional access to industry-leading lab services without the hefty price tag—since 2001, they've been redefining what efficient, patient-focused support looks like. Imagine no hidden fees, no minimums, and only paying for completed tests. Experience lab services that not only meet but also exceed your expectations. Join the co-op trusted by countless licensed clinicians nationwide. Visit www.professionalco-op.com to learn more! This episode is also made possible by Functional Medicine University. FMU is a fully online, self-paced training program in functional medicine, founded in 2006 by Dr. Ron Grisanti. With students in all 50 U.S. states and 68 countries globally, FMU has become a cornerstone in advanced clinical education for healthcare practitioners. The curriculum is led by Dr. Grisanti, alongside contributions from over 70 distinguished medical experts on FMU's advisory board. Graduates earn the prestigious Certified Functional Medicine Practitioner (CFMP®) credential upon completion. FMU is also a nationally approved provider of continuing education for a wide range of licensed professionals, including MDs, DCs, DOs, NDs, acupuncturists, PAs, NPs, nurses, dietitians, pharmacists, and dentists. Whether you're looking to expand your clinical knowledge or bring a functional approach to your practice, FMU offers the tools, guidance, and certification to help you thrive. Visit www.functionalmedicineuniversity.com to learn more!

Dr. Dominic Maneen shares insights on OMT in sports medicine, covering his AT to DO transition and OMT applications for common conditions. Q: How did you transition from an Athletic Trainer (ATC) to a Doctor of Osteopathic Medicine (DO)? A: I transitioned to practicing sports medicine without surgery, as that field didn't align with my interests. I explored osteopathic medicine, identifying the core difference between DOs and MDs as a dedicated course in osteopathic principles. I maintained my athletic training certification to foster understanding and collaboration with ATCs, and a second course focusing on the musculoskeletal system further ignited my passion. During medical school, I also pursued an MBA, gaining insights into medical billing. Q: Can you describe your athletic training (AT) experience at HBU? A: I completed my undergraduate studies at UT, then worked as an ATC for baseball and softball at HBU. I entered the profession serendipitously, drawn by the phrase "sports medicine." It required rapid maturation, as I assumed an adult role despite being only slightly older than the athletes. I collaborated with Richy Valdez and several GAs, and student athletic trainers were indispensable since it was impossible to simultaneously oversee both baseball and softball. I recall an incident involving twin softball players: one sister not playing, the other on deck, with an accidental practice swing hitting the sister, necessitating a golf cart ride to the adjacent facility. Q: Why is low back pain a significant health concern, and how is it related to depression and lifestyle? A: Low back pain is the second most common reason people visit the doctor, with depression being the first. Patients typically present with symptoms that indirectly lead to a depression diagnosis, rather than overtly stating "depression." A sedentary lifestyle is often termed "the new smoking" in medicine, leading to tight, unused muscles. Hands-on manipulation therapy can be beneficial, and simple exercises like push-ups can improve posture by strengthening the neck muscles that support the head. Many individuals struggle with core muscle activation; focusing on proper technique and guiding them to engage their core will lead to increased strength over time. Q: How do you address flat feet in patients? A: Patients often present with concurrent back and knee pain. Structural analysis can reveal the cause, leading to recommendations for inserts or corrective devices for arch support, rather than immediate surgical intervention. Subsequent efforts focus on improving knee mechanics to alleviate symptoms. Q: What is your approach to concussion management? A: Myofascial release may sometimes require trigger point injections. However, most concussion cases can be effectively managed with muscle energy techniques. In older patients, some form of osteopathic manipulation may be necessary. Q: What are the key anatomy considerations for the neck? A: It is crucial to understand that the neck's complexity extends beyond superficial muscles like the scalenes and deltoids; smaller, deeper muscles also play a significant role in neck function. Q: What are your tips for the Athletic Training Room? A: Prioritize hands-on manipulation therapy and muscle energy techniques with athletes, rather than solely relying on stationary bikes or treadmills for warm-up.

In this second half of our deep dive, Melissa Brown, COO of Gravity Consulting, continues her conversation with Melissa Keiter on the critical challenges—and opportunities—of PDPM Medicaid.This episode unpacks real-world strategies for facilities navigating the transition, from documentation pitfalls and audit risks to proactive coordination across nursing, MDS, therapy, and ancillary partners. You'll hear insights on:Why supportive documentation is more important than everHow respiratory therapy, wound care, and psychological services can strengthen your PDPM scoresThe role of coordination between MDS, clinicians, and outside specialistsWhy a proactive, team-based mindset is essential to avoid leaving dollars—and care opportunities—on the tableWhether your state has already transitioned or is still under a rate freeze, this episode will help you prepare your staff, adjust your systems, and avoid the financial and operational risks of falling behind the curve.Support the show

LIVE from Orlando: Dr. Jason Jaeger on Innovation, Politics, and the Future of Chiropractic On August 23rd in Orlando, Florida, history was made. For the very first time, the Crackin' Backs Podcast went LIVE in front of a packed audience at the Florida Chiropractic Convention—and the reaction was nothing short of electric. The energy, the crowd, the conversation—it all came together in a way that proved this show was built for the stage.Our guest for this groundbreaking event was none other than Dr. Jason Jaeger—a chiropractor unlike any other. He's a political advocate in the running for Capitol Hill, the inventor of the Universal Tractioning System, a collaborator who has broken barriers by working alongside MDs and PTs, and a dedicated father balancing it all in Las Vegas. In short—he's a unicorn.This wasn't a TED Talk. This wasn't a lecture. This was a raw, lounge-style conversation about the future of chiropractic, healthcare, and what it really takes to make an impact.In this first-ever LIVE episode, we dive into:How a young chiropractor in 1999 was already lobbying Congress for Medicare reform.The invention of a spinal rehab device born out of necessity—and plenty of duct tape.What it takes to convince MDs and PTs to collaborate instead of compete.The fine line between evidence-based care vs. snake oil salesmanship—and how patients can spot the difference.The never-ending subluxation debate and whether there's finally middle ground.Dr. Jaeger's vision for health freedom and what he'd fight for first in Washington.His blueprint to rebuild American healthcare—and where chiropractic belongs at the table.One powerful call to arms for healthcare providers everywhere.This is more than a conversation—it's a moment. A live show that left the room buzzing and will leave you rethinking what chiropractic can and should be.Now, for the first time, you can experience it too—the full video and audio from our historic live show at the Florida Chiropractic Convention. Learn more about Dr. Jason Jaeger here:Website: HEREInstagram: HEREFacebook: HERE Listen now on Apple Podcasts, Spotify, or watch the full episode on YouTube.We are two sports chiropractors, seeking knowledge from some of the best resources in the world of health. From our perspective, health is more than just “Crackin Backs” but a deep dive into physical, mental, and nutritional well-being philosophies. Join us as we talk to some of the greatest minds and discover some of the most incredible gems you can use to maintain a higher level of health. Crackin Backs Podcast

In this episode, Dr. Olivia Richman discusses her journey in family medicine, the challenges faced by physicians today, and the importance of sexual health education. She highlights the differences between MDs and DOs, her initiatives to combat misinformation in healthcare, and her personal experiences with egg freezing. The discussion also delves into mental health, the physiological aspects of orgasm, and the cultural stigmas surrounding sexuality, emphasizing the need for open conversations about these topics.Chapters00:00 The Versatility of Family Medicine02:46 Challenges of Being a Doctor05:19 Understanding MDs and DOs07:38 Creating Platforms for Medical Influence10:00 The Importance of Sexual Health Education10:47 Mental Health and Personal Growth12:55 Key Sexual Health Issues for Young Women15:21 Cultural Stigmas Around Sexuality17:56 Physiology of Orgasm19:48 Emotional Connection to Sexual Pleasure21:42 Understanding Vaginismus23:38 Olivia's Egg Freezing Journey26:06 Fertility Questions and Concerns27:49 Rapid Fire Topics on Sexual Health30:23 Defining Self-Care and WellbeingContact Dr. RichmanInstagram @Glamourpussmd

The gut microbiome isn't just about digestion, it's the command center influencing everything from mental health and immune resilience to athletic performance and chronic disease risk. In this episode, Dr. Leo Grady unpacks the gut's far-reaching role in human health, highlighting its intricate connections with the immune and nervous systems, nutrient processing, and hormonal regulation. But this conversation goes beyond biology. Dr. Grady introduces cutting-edge innovations in artificial intelligence and genomic sequencing that are reshaping how we study and support the gut. From AI-driven digital twin models to precision dietary and lifestyle interventions, listeners will discover how technology is unlocking a future where gut health can be measured, predicted, and personalized like never before. Whether you're a clinician, health enthusiast, or simply curious about the next frontier in medicine, this episode will change the way you think about your gut and the future of healthcare itself. Key Takeaways: Every aspect of health, including metabolic disorders and mental health, is linked to the gut microbiome. Jonah utilizes advanced AI and genomic sequencing to provide comprehensive gut microbiome analysis. AI's ability to simulate dietary and lifestyle changes can inform personalized health interventions. Shifts in gut microbiome environments indicate possible precursors to diseases like Parkinson's and Alzheimer's. Personalized medicine through AI-driven insights offers an innovative approach to optimize health outcomes. More About Dr. Leo Grady, PhD: Dr. Leo Grady is an internationally recognized leader in applying AI to healthcare, with over 20 years of experience across pioneering startups and global medical companies. As CEO of Paige.ai, he guided the company to industry leadership, launching groundbreaking products worldwide and securing the first-ever FDA approval for an AI product in pathology. Today, as Founder and CEO of Jona, Dr. Grady is spearheading the use of AI and digital twin technology to decode and reshape the gut microbiome, unlocking new ways to transform human health. A prolific innovator, he has authored two books on AI, published over 100 scientific papers, and holds more than 300 patents. His work has earned him the Edison Patent Award and induction as a Fellow of the American Institute for Medical and Biological Engineering. Dr. Grady earned his Ph.D. in Cognitive and Neural Systems from Boston University and currently also serves as CEO in Residence with Breyer Capital. Website Instagram Jona Health's Instagram Facebook Jona Health's LinkedIn Connect with me! Website Instagram Facebook YouTube This episode is sponsored by Professional Co-op®, where clinicians gain exceptional access to industry-leading lab services without the hefty price tag—since 2001, they've been redefining what efficient, patient-focused support looks like. Imagine no hidden fees, no minimums, and only paying for completed tests. Experience lab services that not only meet but also exceed your expectations. Join the co-op trusted by countless licensed clinicians nationwide. Visit www.professionalco-op.com to learn more! This episode is also made possible by Functional Medicine University. FMU is a fully online, self-paced training program in functional medicine, founded in 2006 by Dr. Ron Grisanti. With students in all 50 U.S. states and 68 countries globally, FMU has become a cornerstone in advanced clinical education for healthcare practitioners. The curriculum is led by Dr. Grisanti, alongside contributions from over 70 distinguished medical experts on FMU's advisory board. Graduates earn the prestigious Certified Functional Medicine Practitioner (CFMP®) credential upon completion. FMU is also a nationally approved provider of continuing education for a wide range of licensed professionals, including MDs, DCs, DOs, NDs, acupuncturists, PAs, NPs, nurses, dietitians, pharmacists, and dentists. Whether you're looking to expand your clinical knowledge or bring a functional approach to your practice, FMU offers the tools, guidance, and certification to help you thrive. Visit www.functionalmedicineuniversity.com to learn more!

Dr Azra Raza is a Professor of Medicine, Clinical Director of the Evans Foundation MDS Center, and Executive Director of The First Cell Coalition for Cancer Survivors at Columbia University in New York. She is the best-selling author of "The First Cell: And the human costs of pursuing cancer to the last". She started her research in Myelodysplastic Syndromes (MDS) in 1982 and moved to Rush University, Chicago, Illinois in 1992, where she was the Charles Arthur Weaver Professor in Oncology and Director, Division of Myeloid Diseases. The MDS Program, along with a Tissue Repository containing more than 50,000 samples from MDS and acute leukemia patients was successfully relocated to the University of Massachusetts in 2004 and to Columbia University in 2010. Before moving to New York, Dr Raza was the Chief of Hematology Oncology and the Gladys Smith Martin Professor of Oncology at the University of Massachusetts in Worcester. She has published the results of her laboratory research and clinical trials in prestigious, peer-reviewed journals such as The New England Journal of Medicine, Nature, Blood, Cancer, Cancer Research, the British Journal of Hematology, Leukemia, and Leukemia Research. Dr Raza serves on numerous national and international panels as a reviewer, consultant, and advisor and is the recipient of a number of awards.TIMESTAMPS:(0:00) - Introduction (0:50) - The First Cell: and the human costs of pursuing cancer to the last(4:10) - Defining Cancer(7:50) - A Cancer Paradigm Shift: Finding the First Cell(11:16) - "The Cure for Cancer"(19:05) - Azra's Journey, Development & Reception(24:40) - Hope, Honesty & Harm in a Clinical Setting(33:00) - Current Medical Politics vs Revolutionary Detections/Treatments(39:00) - Increasing Lifespan & Healthspan(43:01) - "Michael Levin Should Win The Nobel Prize!"(51:00) - A Good Life & a Good Death(56:00) - How Words distort our relationship with Disease(1:00:00) - How Disease & Death Shape Our Lives(1:05:40) - The First Cell Book(1:09:15) - A Better Healthcare System(1:12:27) - Conclusion EPISODE LINKS:- Azra's Website: https://azraraza.com- Azra's Books: https://azraraza.com/books- Azra's X: https://x.com/AzraRazaMD- Azra's YouTube: http://www.youtube.com/@AzraRazaMDCONNECT:- Website: https://tevinnaidu.com - Podcast: https://creators.spotify.com/pod/show/mindbodysolution- YouTube: https://youtube.com/mindbodysolution- Twitter: https://twitter.com/drtevinnaidu- Facebook: https://facebook.com/drtevinnaidu - Instagram: https://instagram.com/drtevinnaidu- LinkedIn: https://linkedin.com/in/drtevinnaidu=============================Disclaimer: The information provided on this channel is for educational purposes only. The content is shared in the spirit of open discourse and does not constitute, nor does it substitute, professional or medical advice. We do not accept any liability for any loss or damage incurred from you acting or not acting as a result of listening/watching any of our contents. You acknowledge that you use the information provided at your own risk. Listeners/viewers are advised to conduct their own research and consult with their own experts in the respective fields.

You've heard the figure that most MDs get less than 10-20 hours of nutrition and food training in medical school, and Dr. Katja Rowell (MD!) thinks this is a tragedy.There are some tough moments to hear in this interview, but important ones as we work to raise healthy, independent kids into adulthood.We talked about:What "extreme" picky eating is How bad therapy can hurt a child's relationship with food and family to his/her great detriment, and how you can identify it.Why responsive feeding is different, respectful to the child, and ultimately worlds more effective.Some of the good doctor's regrets about her early years in practice The perils of diet culture for all ages and how we can begin to protect our youth through using the right language and expectationsHow we need to work with extreme and mild picky eaters differently (Spoiler: we don't!)The 5 foundations a good responsive feeding approach boils down to, and how so many families see success Dr. Rowell also said that sugar isn't addictive and doesn't need to be villainized as unhealthy...and with the knowledge and experience I have at this very moment in time, I disagree.But I think it's wonderful that we can learn so much from experts yet also learn to filter everything through our own intellect. I'm totally open to change on this issue, but I also believe it's ok to disagree.Resources We Mention for Extreme Picky EatingDr. Rowell's books: Helping Your Child With Extremely Picky Eating, Conquer Picky Eating for Teens and AdultsTake the free No More Picky Eating Challenge now!Ellyn Satter's Division of ResponsibilitiesMore on feeding a child with sensory processing difficulties, highly sensitive children, and autism from a functional medicine perspectiveYou can connect with Dr. Rowell online at The Feeding Doctor or Extreme Picky EatingFollow her on YouTubeMore resources Dr. Rowell sent me after our interview:Dieticians 4 TeachersThe Feeding Humans PodcastThe Comfort Food Podcast episode on sugarThank you to today's sponsor, Happsy! Shop at kidscookrealfood.com/Happsy for an earth-friendly, affordable mattress today. Kitchen Stewardship Kids Cook Real Food follow Katie on Instagram or Facebook Subscribe to the newsletter to get weekly updates YouTube shorts channel for HPH Find the Healthy Parenting Handbook at kidscookrealfood.com/podcast Affiliate links used here. Thanks for supporting the Healthy Parenting Handbook!

Most people think iron is only a concern if they're deficient, but too much iron can be just as dangerous. In this episode, I sit down with Dr. Christy Sutton, a leading figure in the study of iron imbalances, to explore the often-overlooked health epidemic of unrecognized iron overload. Anchored around her book, The Iron Curse, we discuss why outdated laboratory ranges often fail to detect these imbalances and why recognizing them is so crucial for long-term health. From there, we dive into the intricacies of iron metabolism and the need for updated functional health ranges tailored to healthy populations. Dr. Sutton explains how imbalances can signal underlying health problems and highlights the value of functional lab testing in catching issues conventional methods often miss. We also explore the role of genetic testing—especially for hereditary hemochromatosis—and how genetics and environmental factors work together to influence iron levels. Key Takeaways: Iron Imbalance Epidemic: Iron imbalances, particularly overload, are often underdiagnosed due to outdated lab ranges and misconceptions, representing a silent health epidemic. Functional vs. Conventional Ranges: Functional health ranges, as opposed to traditional lab ranges based on sick populations, are crucial for accurate diagnosis of iron-related health conditions. Importance of Genetic Testing: Genetic factors (hemochromatosis genes) play a significant role in iron overload, necessitating comprehensive testing beyond typical lab work. Dietary and Lifestyle Influences: Both high and low iron levels are influenced by diet, lifestyle, and, importantly, how iron interacts with other nutrients and lifestyle factors like exercise. Gender and Iron Requirements: Iron needs differ significantly by sex and life stages, with menstrual and post-menopausal women, as well as men, needing tailored iron management strategies. More About Dr. Christy Sutton, D.C.: Dr. Christy Sutton is interested in asking why health problems happen and finding the safest and least problematic solutions. Her work takes a deep and meaningful dive into genomics, labs testing and creating a personalized health plan. Her focus on finding and avoiding health landmines early stems from her personal experience with Crohn's and celiac disease plus her husband's experience with high iron, hemochromatosis, and a pituitary tumor that likely was associated with having undiagnosed hemochromatosis. Website Instagram Connect with me! Website Instagram Facebook YouTube This episode is sponsored by Professional Co-op®, where clinicians gain exceptional access to industry-leading lab services without the hefty price tag—since 2001, they've been redefining what efficient, patient-focused support looks like. Imagine no hidden fees, no minimums, and only paying for completed tests. Experience lab services that not only meet but also exceed your expectations. Join the co-op trusted by countless licensed clinicians nationwide. Visit www.professionalco-op.com to learn more! This episode is also made possible by Functional Medicine University. FMU is a fully online, self-paced training program in functional medicine, founded in 2006 by Dr. Ron Grisanti. With students in all 50 U.S. states and 68 countries globally, FMU has become a cornerstone in advanced clinical education for healthcare practitioners. The curriculum is led by Dr. Grisanti, alongside contributions from over 70 distinguished medical experts on FMU's advisory board. Graduates earn the prestigious Certified Functional Medicine Practitioner (CFMP®) credential upon completion. FMU is also a nationally approved provider of continuing education for a wide range of licensed professionals, including MDs, DCs, DOs, NDs, acupuncturists, PAs, NPs, nurses, dietitians, pharmacists, and dentists. Whether you're looking to expand your clinical knowledge or bring a functional approach to your practice, FMU offers the tools, guidance, and certification to help you thrive. Visit www.functionalmedicineuniversity.com to learn more!

Multiple system atrophy is a rare, sporadic, adult-onset, progressive, and fatal neurodegenerative disease. Accurate and early diagnosis remains challenging because it presents with a variable combination of symptoms across the autonomic, extrapyramidal, cerebellar, and pyramidal systems. Advances in brain imaging, molecular biomarker research, and efforts to develop disease-modifying agents have shown promise to improve diagnosis and treatment. In this episode, Casey Albin, MD speaks with Tao Xie, MD, PhD, author of the article “Multiple System Atrophy” in the Continuum® August 2025 Movement Disorders issue. Dr. Albin is a Continuum® Audio interviewer, associate editor of media engagement, and an assistant professor of neurology and neurosurgery at Emory University School of Medicine in Atlanta, Georgia. Dr. Xie is director of the Movement Disorder Program, chief of the Neurodegenerative Disease Section in the department of neurology at the University of Chicago Medicine in Chicago, Illinois. Additional Resources Read the article: Multiple System Atrophy Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @caseyalbin Full episode transcript available here Dr. Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr Albin: Hello everyone, this is Dr Casey Albin. Today I'm interviewing Dr Tao Xie about his article on diagnosis and management of multiple system atrophy, which appears in the August 2025 Continuum issue on movement disorders. Welcome to the podcast, and please introduce yourself to our audience. Dr Xie: Thank you so much, Dr Albin. My name is Tao Xie, and sometimes people also call me Tao Z. I'm a mood disorder neurologist, professor of neurology at the University of Chicago. I'm also in charge of the mood disorder program here, and I'm the section chief in the neurodegenerative disease in the Department of Neurology at the University of Chicago Medicine. Thank you for having me, Dr Albin and Dr Okun and the American Academy of Neurology. This is a great honor and pleasure to be involved in this education session. Dr Albin: We are delighted to have you, and thank you so much for the thoughtful approach to the diagnosis and management. I really want to encourage our listeners to check out this article. You know, one of the things that you emphasize is multiple system atrophy is a fairly rare condition. And I suspect that clinicians and trainees who even have a fair amount of exposure to movement disorders may not have encountered that many cases. And so, I was hoping that you could just start us off and walk us through what defines multiple system atrophy, and then maybe a little bit about how it's different from some of the more commonly encountered movement disorders. Dr Xie: This is a really good question, Dr Albin. Indeed, MSA---multisystem atrophy----is a rare disease. It is sporadic, adult-onset, progressive, fatal neurodegenerative disease. By the name MSA, multisystem atrophy. Clinically, it will present with multiple symptoms and signs involving multiple systems, including symptoms of autonomic dysfunction and symptoms of parkinsonism, which is polyresponsive to the levodopa treatment; and the symptom of cerebellar ataxia, and symptom of spasticity and other motor and nonmotor symptoms. And you may be wondering, what is the cause- underlying cause of these symptoms? Anatomically, we can find the area in the basal ganglia striatonigral system, particularly in the putamen and also in the cerebellar pontine inferior, all of the nuclear area and the specific area involved in the autonomic system in the brain stem and spinal cord: all become smaller. We call it atrophy. Because of the atrophy in this area, they are responsible for the symptom of parkinsonism if it is involved in the putamen and the cerebral ataxia, if it's involved in the pons and cerebral peduncle and the cerebellum. And all other area, if it's involved in the autonomic system can cause autonomic symptoms as well. So that's why we call it multisystem atrophy. And then what's the underlying cellular and subcellular pathological, a hallmark that is in fact caused by misfolded alpha-synuclein aggregate in the oligodontia site known as GCI---glial cytoplasmic increasing bodies---in the cells, and sometimes it can also be found in the neuronal cell as well in those areas, as mentioned, which causes the symptom. But clinically, the patient may not present all the symptoms at the same time. So, based on the predominant clinical symptom, if it's mainly levodopa, polyresponsive parkinsonism, then we call it MSAP. If it's mainly cerebellar ataxia, then we call it MSAC. But whether we call it MSP or MSC, they all got to have autonomic dysfunction. And also as the disease progresses, they can also present both phenotypes together. We call that mixed cerebellar ataxia and parkinsonism in the advanced stage of the disease. So, it is really a complicated disease. The complexity and the similarity to other mood disorders, including parkinsonism and the cerebellar ataxia, make it really difficult sometimes, particularly at the early stages of disease, to differentiate one from the other. So, that was challenging not only for other professionals, general neurologists and even for some movement disorder specialists, that could be difficult particularly if you aim to make an accurate and early diagnosis. Dr Albin: Absolutely. That is such a wealth of knowledge here. And I'm going to distill it just a little bit just to make sure that I understand this right. There is alpha-synuclein depositions, and it's really more widespread than one would see maybe in just Parkinson's disease. And with this, you are having patients present with maybe one of two subtypes of their clinical manifestations, either with a Parkinson's-predominant movement disorder pattern or a cerebellar ataxia type movement disorder pattern. Or maybe even mixed, which really, you know, we have to make things quite complicated, but they are all unified and having this shared importance of autonomic features to the diagnosis. Have I got that all sort of correct? Dr Xie: Correct. You really summarize well. Dr Albin: Fantastic. I mean, this is quite a complicated disease. I would pose to you sort of a case, and I imagine this is quite common to what you see in your clinic. And let's say, you know, a seventy-year-old woman comes to your clinic because she has had rigidity and poor balance. And she's had several falls already, almost always from ground level. And her family tells you she's quite woozy whenever she gets up from the chair and she tends to kind of fall over. But they noticed that she's been stiff,and they've actually brought her to their primary care doctor and he thought that she had Parkinson's disease. So, she started levodopa, but they're coming to you because they think that she probably needs a higher dose. It's just not working out very well for her. So how would you sort of take that history and sort of comb through some of the features that might make you more concerned that the patient actually has undiagnosed multiple systems atrophy? Dr Xie: This is a great case, because we oftentimes can encounter similar cases like this in the clinic. First of all, based on the history you described, it sounds like an atypical parkinsonism based on the slowness, rigidity, stiffness; and particularly the early onset of falls, which is very unusual for typical Parkinson disease. It occurs too early. If its loss of balance, postural instability, and fall occurred within three years of disease onset---usually the motor symptom onset---then it raises a red flag to suspect this must be some atypical Parkinson disorders, including multiple system atrophy. Particularly, pou also mentioned that the patient is poorly responsive to their levodopa therapy, which is very unusual because for Parkinson disease, idiopathic Parkinson disease, we typically expect patients would have a great response to the levodopa, particularly in the first 5 to 7 years. So to put it all together, this could be atypical parkinsonism, and I could not rule out the possibility of MSA. Then I need to check more about other symptoms including autonomic dysfunction, such as orthostatic hypertension, which is a blood pressure drop when the patient stands up from a lying-down position, or other autonomic dysfunctions such as urinary incontinence or severe urinary retention. So, in the meantime, I also have to put the other atypical Parkinson disorder on the differential diagnosis, such as PSP---progressive supranuclear palsy---and the DLBD---dementia with Lewy body disease.---Bear this in mind. So, I want to get more history and more thorough bedside assessment to rule in or rule out my diagnosis and differential diagnosis. Dr Albin: That's super helpful. So, looking for early falls, the prominence of autonomic dysfunction, and then that poor levodopa responsiveness while continuing to sort of keep a very broad differential diagnosis? Dr Xie: Correct. Dr Albin: One of the things that I just have to ask, because I so taken by this, is that you say in the article that some of these patients actually have preservation of smell. In medical school, we always learn that our Parkinson's disease patients kind of had that early loss of smell. Do you find that to be clinically relevant? Is that- does that anecdotally help? Dr Xie: This is a very interesting point because we know that the loss of smelling function is a risk effect, a prodromal effect, for the future development of Parkinson disease. But it is not the case for MSA. Strange enough, based on the literature and the studies, it is not common for the patient with MSA to present with anosmia. Some of the patients may have mild to moderate hyposmia, but not to the degree of anosmia. So, this is why even in the more recent diagnosis criteria, the MDS criteria published 2022, it even put the presence of anosmia in the exclusion criteria. So, highlight the importance of the smell function, which is well-preserved for the majority in MSA, into that category. So, this is a really interesting point and very important for us, particularly clinicians, to know the difference in the hyposmia, anosmia between the- we call it the PD, and the dementia Lewy bodies versus MSA. Dr Albin: Fascinating. And just such a cool little tidbit to take with us. So, the family, you know, you're talking to them and they say, oh yes, she has had several fainting episodes and we keep taking her to the primary care doctor because she's had urinary incontinence, and they thought maybe she had urinary tract infections. We've been dealing with that. And you're sort of thinking, hm, this is all kind of coming together, but I imagine it is still quite difficult to make this diagnosis based on history and physical alone. Walk our listeners through sort of how you're using MRI and DAT scan and maybe even some other biomarkers to help sort of solidify that diagnosis. Dr Xie: Yeah, that's a wonderful question. Yeah. First of all, UTI is very common for patients with MSA because of urinary retention, which puts them into a high risk of developing frequent UTI. That, for some patients, could be the very initial presentation of symptoms. In this case, if we check, we say UTI is not present or UTI is present but we treat it, then we check the blood pressure and we do find also hypertension---according to new diagnosis criteria, starting drop is 20mm mercury, but that's- the blood pressure drop is ten within three minutes. And also, in the meantime the patients present persistent urinary incontinence even after UTI was treated. And then the suspicion for MS is really high right at this point. But if you want increased certainty and a comfortable level on your diagnosis, then we also need to look at the brain MRI mark. This is a required according to the most recent MDS diagnosis criteria. The presence of the MRI marker typical for MSA is needed for the diagnosis of clinically established MSA, which holds the highest specificity in the clinical diagnosis. So then, we have- we're back to your question. We do need to look at the brain MRI to see whether evidence suggestive of atrophy around the putamen area, around the cerebellar pontine inferior olive area, is present or not. Dr Albin: Absolutely. That's super helpful. And I think clinicians will really take that to sort of helping to build a case and maybe recognizing some of this atypical Parkinson's disease as a different disease entity. Are there any other biomarkers in the pipeline that you're excited about that may give us even more clarity on this diagnosis? Dr Xie: Oh, yeah. This is a very exciting area. In terms of biomarker for the brain imaging, particularly brain MRI, in fact, today there's a landmark paper just published in the Java Neurology using AI, artificial intelligence or machine learning aid, diagnoses a patient with parkinsonism including Parkinson's disease, MSA, and PSP, with very high diagnostic accuracy ranging from 96% to 98%. And some of the cases even were standard for autopsy, with pathological verification at a very high accurate rate of 93.9%. This is quite amazing and can really open new diagnosis tools for us to diagnose this difficult disease; not only in an area with a bunch of mood disorder experts, but also in the rural area, in the area really in need of mood disorder experts. They can provide tremendous help to provide accurate, early diagnosis. Dr Albin: That's fantastic and I love that, increasing the access to this accurate diagnosis. What can't artificial intelligence do for us? That's just incredible. Dr Xie: And also, you know, this is just one example of how the brain biomarker can help us. Theres other---a fluid biomarker, molecular diagnostic tools, is also available. Just to give you an example, one thing we know over the past couple years is skin biopsy. Through the immunofluorescent reaction, we can detect whether the hallmark of abnormally folded, misfolded, and the phosphorate, the alpha-synuclein aggregate can be found just by this little pinch of skin biopsy. Even more advanced, there's another diagnosis tool we call the SAA, we call the seizure amplification assay, that can even help us to differentiate MSA from other alpha-synucleinopathy, including Parkinson disease and dementia with Lewy bodies. If we get a little sample from CSF, spinal cerebral fluids, even though this is probably still at the early stage, a lot of developments still ongoing, but this, this really shows you how exciting this area is now. We're really in a fast forward-moving path now. Dr Albin: It's really incredible. So, lots coming down the track in, sort of, MRI, but also with CSF diagnosis and skin biopsies. Really hoping that we can hone in some of those tools as they become more and more validated to make this diagnosis. Is that right? Dr Xie: Correct. Dr Albin: Amazing. We can talk all day about how you manage these in the clinic, and I really am going to direct our listeners to go and read your fantastic article, because you do such an elegant job talking about how this takes place in a multidisciplinary setting, if at all possible. But as a neurointensivist, I was telling you, we have so much trouble in the hospital. We have A-lines, and we have the ability to get rapid KUBs to look at Ilias, and we can have many people as lots of diagnosis, and we still have a lot of trouble treating autonomiclike symptoms. Really, really difficult. And so, I just wanted to kind of pick your brain, and I'll start with just the one of orthostatic hypotension. What are some of the tips that you have for, you know, clinicians that are dealing with this? Because I imagine that this is quite difficult to do without patients. Dr Xie: Exactly. This is indeed a very difficult symptom to deal with, particularly at an outpatient setting. But nowadays with the availability of more medication---to give an example, to treat patients with orthostatic hypertension, we have not only midodrine for the cortisol, we also have droxidopa and several others as well. And so, we have more tools at hand to treat the patient with orthostatic hypertension. But I think the key thing here, particularly for us to the patient at the outpatient setting: we need to educate the patient's family well about the natural history of the disease course. And we also need to tell them what's the indication and the potential side effect profile of any medication we prescribe to them so that they can understand what to expect and what to watch for. And in the meantime, we also need to keep really effective and timely communication channels, make sure that the treating physician and our team can be reached at any time when the patient and family need us so that we can be closely monitoring, their response, and also monitoring potential side effects as well to keep up the quality of care in that way. Dr Albin: Yeah, I imagine that that open communication plays a huge role in just making sure that patients are adapting to their symptoms, understanding that they can reach out if they have refractory symptoms, and that- I imagine this takes a lot of fine tuning over time. Dr Xie: Correct. Dr Albin: Well, this has just been such a delight to get to talk to you. I really feel like we could dive even deeper, but I know for the sake of time we have to kind of close out. Are there any final points that you wanted to share with our listeners before we end the interview? Dr Xie: I think for the patients, I want them to know that nowadays with advances in science and technology, particularly given a sample of rapid development in the diagnostic tools and the multidisciplinary and multisystemic approach to treatment, nowadays we can make an early and accurate diagnosis of the MSA, and also, we can provide better treatment. Even though so far it is still symptomatically, mainly, but in the near future we hope we can also discover disease-modifying treatment which can slow down, even pause or prevent the disease from happening. And for the treating physician and care team professionals, I just want them to know that you can make a difference and greatly help the patient and the family through your dedicated care and also through your active learning and innovative research. You can make a difference. Dr Albin: That's amazing and lots of hope for these patients. Right now, you can provide really great care to take care of them, make an early and accurate diagnosis; but on the horizon, there are really several things that are going to move the field forward, which is just so exciting. Again today, I've been really greatly honored and privileged to be able to talk to Dr Tao Xie about his article on diagnosis and management of multiple system atrophy, which appears in the August 2025 Continuum issue on movement disorders. Be sure to check out Continuum Audio episodes for this and other issues. And thank you again to our listeners for joining us today. Dr Xie: Thank you so much for having me. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

This week in Divorce Summer School, we're breaking down a popular article: “7 Things to Do ASAP When Your Spouse Wants a Divorce” from MSN & Money Talks News—and giving you the MDS-approved version. Karen and Catherine go tip-by-tip to explain what advice holds up, what you should reconsider, and what most people get wrong when panic sets in. If you're unsure how to respond when divorce is suddenly on the table, this episode will help you shift from reaction to strategy. Why hiring an attorney might not be your first step How to run a credit report (and why your score isn't enough) What “entitled” really means in divorce—and why mindset matters How to protect your assets without escalating conflict Smart, emotionally aware ways to talk to your kids What financial clarity actually looks like (and why it changes everything) Start your financial assessment at mydivorcesolution.com Next Week on Divorce Summer School: “Real Life, Real Numbers – Unpacking Financial Case Studies in Divorce.” What You'll Learn:Free Resources: Learn more about your ad choices. Visit megaphone.fm/adchoices

This week on Ditch the Labcoat, Dr. Mark Bonta sits down with Dr. Diana Driscoll, an optometrist, researcher, and internationally recognized authority on the autonomic nervous system—who also happens to be one of the rare non-MDs to join the show. After her own sudden and life-altering health collapse, Dr. Driscoll found herself deep in the world of dysautonomia—a group of disorders affecting the autonomic nervous system, responsible for all those automatic functions in our bodies we don't usually have to think about. Finding few answers from doctors, and confronted by a system that too often shuns “invisible illnesses,” Dr. Driscoll became her own medical detective, pioneering research into conditions like Postural Orthostatic Tachycardia Syndrome (POTS) and unlocking innovative approaches to treatment.In this eye-opening conversation, Dr. Driscoll and Dr. Bonta tackle the complex, often misunderstood world of autonomic dysfunction, the science behind “mystery illnesses,” and the frustrating gaps in our medical knowledge. From the lived experience of being a patient who was told “it's all in your head,” to developing new therapeutics and advocating for others, Dr. Driscoll's story is as inspiring as it is informative.If you've ever struggled with unexplained symptoms, felt dismissed by the healthcare system, or just want to understand the evolving science behind these often-invisible disorders—this episode is for you. Plug in for a candid, practical, and hope-filled discussion that challenges the boundaries of what medicine knows today and explores the frontier where suffering finally meets science.Episode HighlightsInvisible Illness Is Real — Validation for patients with unexplained symptoms is crucial; their suffering is genuine, not imagined or "all in their head."Medicine's Knowledge Blindspots — The medical establishment often lacks answers—and even language—for complex autonomic disorders like dysautonomia and POTS.Patient-Led Discovery Matters — Dr. Driscoll's personal journey from patient to researcher demonstrates the power of self-advocacy in pushing knowledge forward.Autonomic System Ignorance — Most clinicians receive minimal training about the autonomic nervous system, leading to missed diagnoses and inadequate care.One Size Doesn't Fit All — There is no single solution for autonomic dysfunction—treatments must be individualized to each patient's complex presentation.Beyond Symptom Management — Suppressing symptoms (e.g., racing heart) without understanding the root cause can worsen patient outcomes or miss vital clues.The Inflammatory Connection — Inflammation, triggered by infections or stress, can drive autonomic dysfunction—a framework for science to pursue targeted therapies.Necessity of Clinical Innovation — When guidelines and therapies don't exist, scientific curiosity and non-traditional research can inspire new approaches and hope.The Power of Lived Experience — Practitioner-patients like Dr. Driscoll bridge gaps between science, clinical care, and compassion through firsthand understanding.Hope Through Education — Educating both patients and practitioners fosters progress—there's always hope, even if answers come step by step.Episode Timestamps04:15 – Post-COVID Dysautonomia Insights 07:12 – Invisible Illnesses and Tech Misguidance 13:07 – Central Sensitization and Unexplained Symptoms 16:44 – Nicotine Patch Stimulates Vagus Nerve 20:01 – Navigating Illness and Predatory Healthcare 20:51 – Navigating Autonomic Dysfunction Treatments 26:03 – Bridging Medical Knowledge Gaps 29:38 – Idiopathic Intracranial Hypertension Insights 31:25 – Inflammation's Impact on Heart and Vision 36:07 – Chronic Illness: The Domino Effect 41:18 – Questioning Symptom-Driven Treatments 44:22 – Unseen Illness: Recognition Grows 45:26 – Advancements in Autonomic Dysfunction Treatments 49:06 – Championing Long Covid ResearchDISCLAMER >>>>>>    The Ditch Lab Coat podcast serves solely for general informational purposes and does not serve as a substitute for professional medical services such as medicine or nursing. It does not establish a doctor/patient relationship, and the use of information from the podcast or linked materials is at the user's own risk. The content does not aim to replace professional medical advice, diagnosis, or treatment, and users should promptly seek guidance from healthcare professionals for any medical conditions.   >>>>>> The expressed opinions belong solely to the hosts and guests, and they do not necessarily reflect the views or opinions of the Hospitals, Clinics, Universities, or any other organization associated with the host or guests.    Disclosures: Ditch The Lab Coat podcast is produced by (Podkind.co) and is independent of Dr. Bonta's teaching and research roles at McMaster University, Temerty Faculty of Medicine and Queens University. 

Dr. Jen Pfleghaar explains wellness credentials, exposes diploma mills, and reveals red flags to avoid deceptive practitioners in health and wellness.Welcome back to The Integrative Health Podcast! Today, we're diving into something I get asked about all the time — how do you really know who to trust in the wellness world? There's a lot of confusion around credentials and professional titles, and I want to help you cut through the noise.I'm breaking down what those common titles mean — from MDs and DOs to naturopaths, chiropractors, and health coaches. You'll learn why it matters to understand their training, what they're legally allowed to do, and how to spot when someone's using the title “doctor” without full transparency.We'll also talk about the red flags—like those shady online “diploma mills” that offer quick credentials with little oversight—and why mentorship and collaboration among health professionals are so important for your safety and well-being.By the end of this episode, you'll feel more confident navigating the health and wellness landscape and empowered to make choices that truly support your health journey. Let's get into it!PODCAST: Thank you for listening please subscribe and share! Shop supplements: https://healthybydrjen.shop/CHECK OUT a list of my Favorite products here: https://www.healthybydrjen.com/drjenfavorites FOLLOW ME:Instagram :: https://www.instagram.com/integrativedrmom/Facebook :: https://www.facebook.com/integrativedrmomYouTube :: https://www.youtube.com/@integrativedrmom FTC: Some links included in this description might be affiliate links. If you purchase a product through one of them, I will receive a commission (at no additional cost to you). I truly appreciate your support of my channel. Thank you for watching! Video is not sponsored. DISCLAIMER: This podcast does not contain any medical or health related diagnosis or treatment advice. Content provided on this podcast is for informational purposes only. For any medical or health related advice, please consult with a physician or other healthcare professionals. Further, information about specific products or treatments within this podcast are not to diagnose, treat, cure or prevent disease.

In this eye-opening episode, I sit down with Dr. Felice Gersh, one of the foremost voices in functional medicine and women's health, to tackle one of the most misunderstood phases of life—menopause. Together, we unpack the real physiological changes women face during this transition, and the often-overlooked health risks that come with it. This isn't just about “hot flashes”—we're talking sleep disruption, cardiovascular risk, insulin resistance, and the metabolic shifts that can alter a woman's long-term health trajectory. Dr. Gersh pulls back the curtain on estradiol, reframing it as a life hormone—not simply a “sex hormone.” We explore why its decline affects nearly every system in the body, and how lifestyle strategies, functional medicine insights, and targeted interventions can help women not just survive menopause, but thrive through it. Whether you're in the midst of this change or helping patients navigate it, this conversation delivers the clarity, science, and hope you need to take control of health during this critical stage of life.Key Takeaways: Hormonal Shift: Menopause leads to a decline in estradiol produced by ovaries, affecting every organ system and increasing health condition risks, including cardiovascular diseases and metabolic disorders. Holistic Understanding: Dr. Gersh advocates for a comprehensive understanding of hormones in menopause, emphasizing the necessity of a proactive rather than reactive treatment approach. Testing and Diagnosis: She outlines important blood tests and diagnostic markers, such as day 3 FSH, thyroid function, inflammatory markers, and lipid profiles to better navigate menopause management. Lifestyle Interventions: Key lifestyle changes, including diet rich in plants, exercise, and stress management, are essential in promoting well-being during and beyond menopause. Functional Medicine Approach: Understanding the interconnectedness of bodily systems and the foundational role of lifestyle and hormonal therapy in women's health is crucial. More About Dr. Felice Gersh: Felice Gersh, M.D. is a multi-award winning physician with dual board certifications in OB-GYN and Integrative Medicine. She is the founder and director of the Integrative Medical Group of Irvine, a practice that provides comprehensive health care for women by combining the best evidence-based therapies from conventional, naturopathic, and holistic medicine. For 12 years, she taught obstetrics and gynecology at Keck USC School of Medicine as an Assistant Clinical Professor, and she now serves as an Affiliate Faculty Member at the Fellowship in Integrative Medicine through the University of Arizona School of Medicine. Felice is a prolific writer and lecturer who speaks globally on women's health and regularly publishes in peer-reviewed medical journals. She is the bestselling author of the PCOS SOS series and her latest book, Menopause: 50 Things You Need to Know. Her research focuses on women's hormones, metabolism, aging, and menopause. Whether she's mentoring medical students, writing groundbreaking books and medical articles, or guiding her patients, Dr. Gersh's mission remains constant: Empower women to thrive in harmony with their bodies and their health. Website Instagram Facebook Connect with me! Website Instagram Facebook YouTube This episode is sponsored by Professional Co-op®, where clinicians gain exceptional access to industry-leading lab services without the hefty price tag—since 2001, they've been redefining what efficient, patient-focused support looks like. Imagine no hidden fees, no minimums, and only paying for completed tests. Experience lab services that not only meet but also exceed your expectations. Join the co-op trusted by countless licensed clinicians nationwide. Visit www.professionalco-op.com to learn more! This episode is also made possible by Functional Medicine University. FMU is a fully online, self-paced training program in functional medicine, founded in 2006 by Dr. Ron Grisanti. With students in all 50 U.S. states and 68 countries globally, FMU has become a cornerstone in advanced clinical education for healthcare practitioners. The curriculum is led by Dr. Grisanti, alongside contributions from over 70 distinguished medical experts on FMU's advisory board. Graduates earn the prestigious Certified Functional Medicine Practitioner (CFMP®) credential upon completion. FMU is also a nationally approved provider of continuing education for a wide range of licensed professionals, including MDs, DCs, DOs, NDs, acupuncturists, PAs, NPs, nurses, dietitians, pharmacists, and dentists. Whether you're looking to expand your clinical knowledge or bring a functional approach to your practice, FMU offers the tools, guidance, and certification to help you thrive. Visit www.functionalmedicineuniversity.com to learn more!

Show notes: (0:00) Intro (0:58) Dr. Michelle's health crisis and how she got into holistic health (6:37) Rethinking fluoride and safer alternatives (12:26) The right kind of mouthwash (16:15) Benefits of copper tongue scrapers (20:07) Prebiotics vs probiotics for oral health (22:37) The hidden dangers of root canals (32:23) Shifting into holistic health care (39:45) Diet, oxygen, and cellular energy (45:13) Where to learn more and find holistic dentists (46:22) Outro Who is Dr. Michelle Jorgensen?   Dr. Michelle Jorgensen is an author, speaker, teacher, biologic/holistic dentist, and health and wellness, provider. After practicing traditional dentistry for 10 years, Michelle became very sick. Through her own path to return to health, she discovered she had mercury poisoning from drilling out mercury fillings for her patients.   Michelle is a Functional Integrative Dentist (DDS) and a Board Certified Traditional Naturopath(BCTN).  She has received certifications as a Therapeutic Nutritional Counselor(TNC) and a Certified Nutritional Autoimmune Specialist(CNAS).  She is constantly pursuing training in health-based dentistry, plant based medicine, organic gardening and more from institutions around the world.    Dr. Jorgensen also teaches and coaches groups of health care professionals from across the country who come to learn the Total Care Way.  Her goal is to change the way health practitioners look at health and open their eyes to a truly integrative model.  This group includes Dentists, Chiropractors, Naturopaths, MDs, Nurse Practitioners, Nutritionists, Massage Therapists and more. Connect with Dr. Jorgensen: Website: https://livingwellwithdrmichelle.com/ IG: https://www.instagram.com/livingwellwithdrmichelle/ FB: https://www.facebook.com/livingwellwithdrmichelle YT: https://www.youtube.com/c/LivingwellwithDrMichelle Links and Resources: Peak Performance Life Peak Performance on Facebook Peak Performance on Instagram

Until now, sports medicine has been highly influenced by the MDs who treat injury so we often follow suit as acupuncturists. Functional Acupuncture is always looking at the whole picture. We can treat more than just the injury. We can look up the chain or into the past to find healthy muscles to optimize and improve sports performance and avoid injury.    Learn more about Functional Acupuncture with my Online Courses on Podia: https://richardhazel.podia.com      

Review of IMerge phase 3 data on imetelstat for lower-risk MDS and how prior therapies affect treatment outcomes, and other ASCO 2025 MDS updates with Andrew Brunner, MD.

In this episode, we speak with Sarah Gebauer MD anesthesiologist and RAND Senior Researcher, who discusses the critical questions facing healthcare professionals as AI becomes integrated into clinical practice. She's the author of "Machine Learning for MDs" newsletter  and published research on physician attitudes toward AI including the BMJ Evidence-Based Medicine article Survey of US physicians' attitudes and knowledge of AI. Her company Validara Health works on evaluation frameworks for healthcare AI implementation. Physicians have been using AI for EKG interpretation for decades without fully understanding the algorithms, highlighting that transparency should focus on appropriate usage rather than complete technical knowledge. Most current AI tools operate as Software as a Service rather than regulated Medical Devices, while the FDA struggles to keep pace with rapid AI development. Despite their challenging history with EHR implementation, physicians show strong interest in learning about AI when they believe it will help patients. The medical liability landscape remains uncertain until legal precedents are established through jury awards, making documentation of clinical decision-making crucial when using AI as additional information alongside other clinical data. Traditional machine learning evaluation metrics often fail to predict real-world clinical performance, where workflow integration and clinician experience prove more important than laboratory results. For professional development, busy physicians benefit most from resources that push information directly to them, such as newsletters and targeted social media follows, rather than formal courses requiring active searching. Some places to follow along with AI in healthcare: Machine Learning for MDs newsletter TLDR AI newsletter a16z healthcare If you enjoy the show, please leave a ⭐⭐⭐⭐⭐ rating on Apple or a

What if the spaces we live, learn, and heal in could actually heal us back?In this powerful podcast interview, we sit down with Janet Roche, MDS, CAPS—nationally recognized design practitioner, educator, and founder of the Trauma-Informed Design Society. Janet is a pioneer in Trauma-Informed Design, helping reshape architecture and interior design to be inclusive, empathetic, and deeply human.We dive into:Her personal journey and the experiences that shaped her visionHow design can either harm or healThe myths around “good” design and disabilityCreating safe spaces for unseen traumaWhat it really costs to center inclusionThe tension between beauty and healingWhether you're a designer, educator, social worker, architect—or simply someone who believes in a more just and humane world—this episode will change how you see the spaces around you.

In this episode, I sit down with Dr. Ben Weitz, a chiropractor with nearly four decades of experience and a deep-rooted passion for functional medicine. After suffering a serious bone injury on Halloween 2023, Dr. Weitz turned his own recovery into a masterclass in functional healing—skipping surgery and injections in favor of peptides, targeted supplementation, and upstream thinking. This isn't theory—it's application. We unpack what worked, what didn't, and why root-cause resolution still matters most. We dive into key healing tools like Forteo, collagen, and vitamin D3 + K2, while also covering deeper concepts like mTOR, longevity science, and why chiropractors often lead the way in integrative care. It's a powerful reminder that movement dysfunction, not just aging, is the true driver of poor health—and that healing starts when you treat the system, not just the symptom. Key Takeaways: Functional Medicine's Role in Healing: Dr. Ben Weitz utilized a functional medicine approach, including advanced supplements and anabolic compounds, to address a severe femur fracture. Integration in Medicine: The conversation highlights the importance of integrating functional medicine with conventional treatment strategies for optimal health outcomes. Focus on Longevity: Contrary to mainstream views, the discussion embraces a balanced approach to mTOR regulation, emphasizing muscle maintenance for longevity. Importance of Quality Nutrition: Dr. Weitz emphasizes the necessity of clean, quality supplements and a balanced diet rich in colorful vegetables, quality protein, and healthy fats. Exercise as a Health Pillar: The episode stresses the vital role of regular physical activity, particularly resistance training, for maintaining bone density and overall longevity. More About Dr. Ben Weitz: Dr. Ben Weitz is a Los Angeles-based sports chiropractor and functional medicine practitioner with over 35 years of clinical experience. He is the founder of Weitz Sports Chiropractic and Nutrition, where he helps patients address chronic pain and optimize long-term health through an integrative, root-cause approach. Dr. Weitz is also the host of the Rational Wellness podcast, where he interviews top experts in health and medicine, diving deep into topics like gut health, hormone balance, and longevity strategies. His passion lies in bridging chiropractic care with evidence-based functional medicine to support healing, performance, and preventive wellness. Website Instagram Facebook Connect with me! Website Instagram Facebook YouTube This episode is sponsored by Professional Co-op®, where clinicians gain exceptional access to industry-leading lab services without the hefty price tag—since 2001, they've been redefining what efficient, patient-focused support looks like. Imagine no hidden fees, no minimums, and only paying for completed tests. Experience lab services that not only meet but also exceed your expectations. Join the co-op trusted by countless licensed clinicians nationwide. Visit www.professionalco-op.com to learn more! This episode is also made possible by Functional Medicine University. FMU is a fully online, self-paced training program in functional medicine, founded in 2006 by Dr. Ron Grisanti. With students in all 50 U.S. states and 68 countries globally, FMU has become a cornerstone in advanced clinical education for healthcare practitioners. The curriculum is led by Dr. Grisanti, alongside contributions from over 70 distinguished medical experts on FMU's advisory board. Graduates earn the prestigious Certified Functional Medicine Practitioner (CFMP®) credential upon completion. FMU is also a nationally approved provider of continuing education for a wide range of licensed professionals, including MDs, DCs, DOs, NDs, acupuncturists, PAs, NPs, nurses, dietitians, pharmacists, and dentists. Whether you're looking to expand your clinical knowledge or bring a functional approach to your practice, FMU offers the tools, guidance, and certification to help you thrive. Visit www.functionalmedicineuniversity.com to learn more! For over 50 years, NutriDyn has been a leader in functional nutrition, supporting healthcare practitioners with science-based supplements and unparalleled education. Since 1973, they've pioneered practitioner-exclusive formulas backed by rigorous testing and built on the latest research—delivering quality and peace of mind in every bottle. NutriDyn is more than just a supplement provider. They're committed to empowering practitioners through world-class educational resources, including national conferences, workshops, and seminars led by industry thought leaders. From clinical support to dedicated sales reps, NutriDyn offers an integrated approach to help elevate your practice and patient outcomes. Trusted. Transparent. Practitioner-focused. Join NutriDyn's wellness community and discover functional nutrition tailored for you—create your account today to take the first step toward better health: https://nutridyn.com/mprofile

The clock is ticking. With the mandatory transition to PDPM Medicaid coming October 1st, many providers are still unprepared—and it's already impacting their margins.In this episode, Melissa Brown is joined by Melissa Keiter, MDS expert and Lead Consultant for Nursing Services at Gravity Consulting, to break down the real-world implications of this sweeping policy shift. From reimbursement cuts to team readiness, they explore why relying on therapy-driven documentation is no longer enough—and what nursing homes must do to avoid sinking under PDPM Medicaid.You'll learn:Why some facilities are already losing $5–$15 per patient per dayHow Section GG impacts your bottom line—and why nurse aides hold the keyWhat to do if your state is including therapy in the Medicaid rateTactical strategies for nursing-only statesHow to prepare your entire care team—from dietitians to social workersThis is part one of a two-part series. Don't miss this critical conversation designed to help you protect your CMI and stay financially afloat during the transition.Support the show

We love to hear from our listeners. Send us a message.Cell & Gene: The Podcast Host, Erin Harris, talks to Orca Bio CEO and Co-Founder Nathaniel Fernhoff as he recounts the company's origins and evolution, tracing its roots to pioneering stem cell research at Stanford University and Dr. Irv Weissman's lab. Seeking to create safer, more effective cures for blood cancers such as AML, ALL, and MDS, Orca Bio developed high-precision cell therapies that utilize purified regulatory T cells and stem cells to minimize complications, such as graft-versus-host disease. Orca Bio spun out of academia to establish its own scalable production platform and clinical pipeline, and Fernhoff explains Orca's flagship product, Orca T, which recently achieved a pivotal milestone by outperforming standard stem cell transplants in a Phase 3 trial.Subscribe to the podcast!Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn

In this powerful episode, I sit down with someone who truly embodies grit, discipline, and the underdog advantage. From catching passes alongside Joe Montana to lining up against legends like Deion Sanders, JJ Birden's journey isn't just about athleticism—it's about mindset. What stood out most to me is how JJ turned obstacles into stepping stones. Despite being overlooked early on, he made it to the NFL through sheer determination and a no-excuses mentality. His stories from the field are more than just entertaining—they're lessons in perseverance, strategic thinking, and personal accountability. But his journey didn't stop when he left the game. JJ shares how he applied the same principles to entrepreneurship, launching his brand Beat the Coverage—a six-step framework for recognizing opportunity and winning in life. He breaks it all down in this episode, along with the health and wellness habits that keep him sharp and performing at his best today. This isn't just a highlight reel—it's a masterclass in resilience. If you've ever felt like the odds were stacked against you, this conversation is your playbook for rising above it. Key Takeaways: Resilience & Mindset: JJ Birden emphasizes the power of resilience and a strong mindset in overcoming barriers and achieving goals against the odds. Transition from Sports to Entrepreneurship: Birden discusses his career shift, leveraging his football experiences to motivate and guide others in their personal and professional journeys. "Beat the Coverage" Framework: JJ introduces a six-step framework designed to spot and exploit opportunities in life's challenges, aligning with his personal narrative. Health and Wellness Commitment: Maintaining a healthy lifestyle is crucial to Birden, who shares practical tips and routines that contribute to his well-being at age sixty. Family First: Birden and his wife made a significant impact on their family by adopting his five nieces and nephews, expanding their household from five to ten, showing immense dedication and love. More About JJ Birden: Born June 16, 1965, in Portland, Oregon, JJ's athletic prowess earned him a track scholarship to the University of Oregon. He walked on to the football team and later excelled in both football and track & field In the 1988 NFL Draft, JJ was selected in the 8th round by the Cleveland Browns and went on to play nine seasons as a wide receiver, surpassing the average NFL career length of under two years Despite standing just 5'10" and weighing 157 lbs, he defied the odds, overcoming injuries and even being turned down by four teams in five days to establish himself as a key player with the Browns, Chiefs, Falcons, and a stint with the Cowboys After retiring, JJ didn't slow down. He became a successful entrepreneur in the health and wellness space, distributing Isagenix products and building multiple ventures. He also spent years preparing for life after football, serving as a track coach, raising funds, investing, and coaching youth, then launched a career as a motivational speaker and performance coach JJ's signature speak­ing style blends stories from his NFL experience, playing two seasons with Hall‑of‑Famer Joe Montana, with clear, actionable strategies designed to help audiences in business and life "seize their opportunities" bestselling book, When Opportunity Knocks: 8 Surefire Ways to Take Advantage!, captures the principles he lives by, and teaches others to follow He and his college sweetheart, Raina, have been married over 35 years and live in the Phoenix area, raising three children and five nieces and nephews under their roof. Through his speaking, coaching, and writing, JJ inspires people everywhere to embrace their underdog spirit, push past limitations, and take bold steps toward their full potential. Website Instagram Facebook Connect with me! Website Instagram Facebook YouTube This episode is sponsored by Professional Co-op®, where clinicians gain exceptional access to industry-leading lab services without the hefty price tag—since 2001, they've been redefining what efficient, patient-focused support looks like. Imagine no hidden fees, no minimums, and only paying for completed tests. Experience lab services that not only meet but also exceed your expectations. Join the co-op trusted by countless licensed clinicians nationwide. Visit www.professionalco-op.com to learn more! This episode is also made possible by Functional Medicine University. FMU is a fully online, self-paced training program in functional medicine, founded in 2006 by Dr. Ron Grisanti. With students in all 50 U.S. states and 68 countries globally, FMU has become a cornerstone in advanced clinical education for healthcare practitioners. The curriculum is led by Dr. Grisanti, alongside contributions from over 70 distinguished medical experts on FMU's advisory board. Graduates earn the prestigious Certified Functional Medicine Practitioner (CFMP®) credential upon completion. FMU is also a nationally approved provider of continuing education for a wide range of licensed professionals, including MDs, DCs, DOs, NDs, acupuncturists, PAs, NPs, nurses, dietitians, pharmacists, and dentists. Whether you're looking to expand your clinical knowledge or bring a functional approach to your practice, FMU offers the tools, guidance, and certification to help you thrive. Visit www.functionalmedicineuniversity.com to learn more! For over 50 years, NutriDyn has been a leader in functional nutrition, supporting healthcare practitioners with science-based supplements and unparalleled education. Since 1973, they've pioneered practitioner-exclusive formulas backed by rigorous testing and built on the latest research—delivering quality and peace of mind in every bottle. NutriDyn is more than just a supplement provider. They're committed to empowering practitioners through world-class educational resources, including national conferences, workshops, and seminars led by industry thought leaders. From clinical support to dedicated sales reps, NutriDyn offers an integrated approach to help elevate your practice and patient outcomes. Trusted. Transparent. Practitioner-focused. Join NutriDyn's wellness community and discover functional nutrition tailored for you—create your account today to take the first step toward better health: https://nutridyn.com/mprofile

Confused by health “experts” online? Learn how to tell if your wellness professional is truly qualified. Dr. Jen Pfleghaar explains credentials, red flags, and what you must verify.Dr. Jen Pfleghaar goes solo in this important episode to clear up confusion about professional labels and credentials in the health and wellness world. In an age when everyone on social media calls themselves a “doctor” or “expert,” she shares exactly how to tell who's qualified—and who isn't.Dr. Jen explains the rigorous training that licensed MDs, DOs, chiropractors, and physician assistants undergo, contrasting them with unregulated programs and diploma mills that produce unqualified “experts.” You'll learn why transparency about training, clear scope of practice, and proper licensure matter for your safety—and how to spot red flags fast.We also explore why so many people are harmed by health coaches or influencers stepping beyond their legal scope and how to do your own due diligence before trusting someone with your health.If you've ever wondered what all those letters after someone's name mean—or if you've felt overwhelmed by conflicting advice online—this episode empowers you to ask the right questions and protect yourself.Dr. Jen Pfleghaar, DO, ABOIM, hosts this solo episode to demystify the credentials behind health professionals and wellness influencers. From MDs and DOs to health coaches and PhDs, she shares how to distinguish rigorous training from unqualified self-promotion—so you can make informed decisions about your care.PODCAST: Thank you for listening please subscribe and share! Shop supplements: https://healthybydrjen.shop/CHECK OUT a list of my Favorite products here: https://www.healthybydrjen.com/drjenfavorites FOLLOW ME:Instagram :: https://www.instagram.com/integrativedrmom/Facebook :: https://www.facebook.com/integrativedrmomYouTube :: https://www.youtube.com/@integrativedrmom FTC: Some links included in this description might be affiliate links. If you purchase a product through one of them, I will receive a commission (at no additional cost to you). I truly appreciate your support of my channel. Thank you for watching! Video is not sponsored. DISCLAIMER: This podcast does not contain any medical or health related diagnosis or treatment advice. Content provided on this podcast is for informational purposes only. For any medical or health related advice, please consult with a physician or other healthcare professionals. Further, information about specific products or treatments within this podcast are not to diagnose, treat, cure or prevent disease.

Dave Rubin of “The Rubin Report” talks to Jillian Michaels about society's obsession with youth and cosmetic procedures; the importance of healthspan over lifespan; the dangers of extreme anti-aging therapies like stem cells and peptides; the risks wealthy individuals face with unproven treatments; how to vet fitness and longevity advice in a world of conflicting health information and online influencers; why she defers to MDs and PhDs over internet trends; her decision to avoid metformin and methylene blue; and how she overcame severe back pain through rehab and smart spine care; cognitive decline in the modern world; how processed food and endless information may be aging our brains faster than in past generations; why diet, genetics, and neuroprotective habits matter; how media bias suppresses legitimate questions about vaccine safety; the importance of critical thinking around public health policies; the role of Big Pharma funding in mainstream media narratives; media bias and truth in podcasting; how influencers should take personal responsibility when discussing complex topics; the lack of transparency around the hepatitis B vaccine and its potential risks; how lobbying by Big Pharma shaped vaccine mandates; how she would handle vaccinating her kids based on disease risk; and the need for people to research for themselves, especially on childhood immunizations; and much more.